EP0651663B1 - Verfahren für nadellose subkutaninjektionen - Google Patents

Verfahren für nadellose subkutaninjektionen Download PDF

Info

Publication number
EP0651663B1
EP0651663B1 EP93918344A EP93918344A EP0651663B1 EP 0651663 B1 EP0651663 B1 EP 0651663B1 EP 93918344 A EP93918344 A EP 93918344A EP 93918344 A EP93918344 A EP 93918344A EP 0651663 B1 EP0651663 B1 EP 0651663B1
Authority
EP
European Patent Office
Prior art keywords
ampule
valve
pressure
poppet
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93918344A
Other languages
English (en)
French (fr)
Other versions
EP0651663A4 (de
EP0651663A1 (de
Inventor
Steven Fisher Peterson
Charles Neal Mckinnon, Jr.
Paul Edward Smith
Takaaki Nakagawa
Victor Leon Bartholomew
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioject Inc
Original Assignee
Bioject Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioject Inc filed Critical Bioject Inc
Publication of EP0651663A1 publication Critical patent/EP0651663A1/de
Publication of EP0651663A4 publication Critical patent/EP0651663A4/de
Application granted granted Critical
Publication of EP0651663B1 publication Critical patent/EP0651663B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
    • A61M2005/31516—Piston or piston-rod constructions, e.g. connection of piston with piston-rod reducing dead-space in the syringe barrel after delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum

Definitions

  • the present invention relates to a needleless hypodermic injection method.
  • Various needleless hypodermic injection devices have been known and used in the past for performing the method according to the invention. These devices, also known as jet injectors, typically use spring or compressed gas driven plungers to accelerate an injectant to a velocity sufficient to pierce through the skin and enter the underlying tissues.
  • US-A-4722728 discloses an injector which pressurizes a fluid injectant within an ampule by driving a plunger into the ampule with sufficient force to expel the desired volume of fluid.
  • Jet injection avoids or diminishes these disadvantages.
  • the characteristics of needleless or jet injections typically vary with the pressures exerted by the injection device, the nozzle diameter of the ampule, the patient's size, age and weight, the nature of the injection site, and the viscosity of the injectant.
  • a long standing basic difficulty with jet injection has been the complex problem of determining which are the preferred injection variables. These variables include: 1) pressure profile, 2) nozzle size, 3) patient factors, i.e., age, sex and size, 4) injection site, and 5) medication viscosity.
  • the repeated failures of the prior art to adequately solve these complex variables problems has contributed to the lack of acceptance of a handheld and portable jet injector in the medical community.
  • the pressure profile is the pressure exerted on the liquid injectant, typically measured over time, from the beginning to the end of the injection.
  • the pressure profile must be selected, in combination with the nozzle size and other factors, to deliver the injectant through the skin to the desired depth, preferably with minimum pain.
  • the patient factors are also important. Gender is significant as women typically have a different adipose distribution than men. Men also typically have tougher tissue that women. The patient's age is important because infants are born with very little muscle, thick layers of adipose, and very easily penetrated skin. As infants age and become mobile the adipose is gradually replaced by muscle. At adolescence the introduction of hormones changes tissue composition. Aging through mid-life is usually associated with gradual weight gain and decrease in tissue strength.
  • Injection sites are very significant because in all patients the thickness of the skin and adipose tissue varies at different regions of the body.
  • the medical profession has established generally accepted injection sites for conventional needle syringes that are best suited for specific types of injection.
  • the subcutaneous sites typically have a thick adipose layer and are free of major nerves and vasculature.
  • Intramuscular sites typically have a thin adipose layer, a thick muscle layer, and are free of major nerves and vasculature.
  • the viscosity of the injectant must be considered as it effects characteristics of the jet injection.
  • viscosity effects have been widely misunderstood in the prior art.
  • jet injection despite its great potential advantages, remains virtually unused. Accordingly, it is an object of the invention to provide an improved method for needleless injection, so That the advantages of jet injection may be brought into use.
  • the pressure profiles of the injectant, nozzle diameter, patient and injection site parameters, as well as injectant viscosity, are selected to achieve desired injection characteristics.
  • the injectant is purposely deposited on the deep fascia in a thin sheet. This provides rapid absorption into the blood stream, without the invasiveness, injection discomfort, and occasional post injection soreness associated with injection deep into the muscle.
  • an injector or needleless injection device 20 which performs the method of the present invention has a front end 22 , a back end 24 , a top surface 26 and a bottom surface 28 .
  • a trigger 30 is slidably mounted on the injector 20 adjacent the bottom surface 28 .
  • the injector 20 includes an upper housing 42 and a shorter lower housing 44 attached to the upper housing 42 .
  • the lower housing 44 has a flat upper surface 82 which lies against a flat lower surface 84 of the upper housing 42 .
  • the upper housing 42 and lower housing 44 are attached together with four (4) pins 86 .
  • the upper housing 42 and lower housing 44 together are sized and shaped to readily fit the user's hand, with the user's palm resting over the top surface 26 and side of the injector 20 , and with the user's index finger easily positionable over the trigger 30 .
  • the top surface 26 has a step or incline 34 at approximately the center of the injector 20 .
  • the upper and lower housings may alternatively be formed as a single housing.
  • the lower housing 44 is substantially hollow and defines a lower housing space 48 .
  • the upper housing 42 defines an upper housing space 46 (Fig. 6).
  • a cartridge chamber 50 for receiving and holding a compressed gas cartridge 54 , e.g., a CO 2 cartridge.
  • a cartridge seat 52 at the forward end of the cartridge chamber 50 supports the back of the cartridge 54 .
  • a generally u-shaped plastic cartridge chamber cover 56 snaps into place on the lower housing 44 over the cartridge chamber 50 .
  • a generally cylindrical piercing housing 58 is slidably positioned behind the cartridge chamber 50 within the lower housing 44 .
  • O-rings 60 seal the piercing housing 58 against the lower housing 44 while allowing the piercing housing 58 to slide within the lower housing 44 .
  • An annulus 62 extends around the circumference of the piercing housing 58 in between the o-rings 60 .
  • a cylindrical piercing body 66 is positioned within the piercing housing 58 and sealed against the piercing housing 58 by o-rings 88 .
  • a piercing point 68 extends forward from the front surface of the piercing body 66 and is centrally aligned with the neck of the cartridge 54 .
  • a seal 64 on the front end of the piercing body 66 surrounds the piercing point 68 . The seal 64 extends sufficiently forward to seal against the neck of the cartridge 54 before the piercing point 68 penetrates into the cartridge 54 .
  • a bore 70 extends through the piercing point 68 and piercing body 66 connecting to the annulus 62 .
  • a piercing body nut 74 threads into the back end of the piercing housing 58 , to secure the piercing body 66 and seal 64 in position within and against the forward end of the piercing housing 58 .
  • a piercing housing nut 76 threads into the back of the lower housing 44 . Spanner tool openings are provided in the piercing body nut 74 and the piercing housing nut 76 for assembly purposes.
  • a threaded shaft 72 extends through and engages threads in the piercing housing nut 76 .
  • a knob 78 attached to the threaded shaft 72 has a flip handle 80 which can be flipped up perpendicular to the plane of the knob 78 to allow the knob 78 and threaded shaft 72 to be more easily tuned by hand.
  • the forward end of the Threaded shaft 72 bears against the back surface of the piercing body 66 .
  • a hole 92 extends through the upper surface 82 of the lower housing to connect the annulus 62 to a bore 96 leading into the upper housing space 46 .
  • An o-ring 94 seals the connection of the hole 92 and bore 96 .
  • a transparent window lens 98 secured to an end nut 108 by a rubber window retainer 100 .
  • a Bourdon tube 116 is soldered into a gauge base 114 and has an open end 124 extending into a gauge chamber 122 .
  • the pointer 102 extends perpendicularly from the back end of the Bourdon tube 116 .
  • a gauge label 104 applied to the back end of a gauge body 106 around the Bourdon tube 116 provides a calibrated pressure scale with the scale and pointer visible through the lens 98 . Stop pins extending from the back end of the gauge body 106 provide high and low pressure end point stops for the pointer 102 .
  • the end nut 108 has threads 110 at its forward end which engage the upper housing 42 .
  • the gauge body 106 is rotated relative to the gauge base 114 .
  • the gauge body 106 and gauge base 114 are adhered together.
  • a guiding pin 112 extends from the upper housing 42 into a keyway groove and holds the gauge body 106 in place while the end nut 108 is tightened.
  • Shims 118 are provided at the front surface at the gauge base 114 , as required, for proper stack up and positioning of components in the upper housing 42 .
  • An initiator valve housing 142 is spaced apart from the gauge base 114 by a filter retainer ring 120 .
  • a sandwiched assembly of filter disks 130 and synthetic filters 132 are contained within the back end of the housing 142 .
  • O-rings 140 seal the filter disks 130 against the retainer 140 and synthetic filter 132 .
  • O-ring 126 seals the filter retainer 140 within the upper housing 42.
  • O-ring 126 and o-ring 150 seal the gauge chamber 122 such that compressed gas provided Through the bore 96 can flow out of the gauge chamber 122 only through the filters.
  • a port 148 extends through the back wall of the initiator valve housing 142 into an initiator valve chamber 146 within the housing 142 .
  • An initiator valve 144 within the initiator valve chamber 146 controls gas flow from the port 148 through the initiator valve chamber 146 to a reservoir port 154 formed through the forward wall of the initiator valve housing 142 .
  • a regulation valve 156 includes a regulation seat 158 formed around the reservoir port 154 .
  • a dart 160 moves into and out of the regulation seat 158 .
  • the dart 160 has a threaded dart shaft 162 Threaded into the narrower tube section at the back end of a poppet body 172 .
  • a dart pin 164 extending through the tube section of the poppet body 172 and the threaded dart shaft 162 secures the adjustment of the longitudinal position of the dart 160 in relation to the regulation seat 158 .
  • a reservoir spacer 166 within the upper housing 42 extends from the forward end of the initiator valve housing 142 to a poppet housing 178 , forming a reservoir 168 around the tube section of the poppet body 172 .
  • O-rings 126 seal the reservoir spacer 166 against the upper housing 42 and seal the initiator valve housing 142 to the reservoir spacer 166 .
  • a poppet valve 170 within the poppet housing 178 has a conical plastic poppet seat 188 centered within and positioned against a forward wall of the poppet housing 178 .
  • the poppet body 172 has a sharp sealing edge 200 biased against the poppet seat 188 by a compression spring 186 held in position within the poppet housing 178 by a poppet nut 180 .
  • the sealing edge 200 and poppet seat 188 may be configured with unlike angles selected so that the inner diameter contacts first, to minimize creep effects.
  • the poppet nut 180 has a threaded forward section 184 engaged to a threaded rear section 182 of the poppet housing 178 .
  • the poppet nut 180 is tuned to adjust the compression on the spring 186 and correspondingly set the cracking pressure of the poppet valve 170 .
  • the diameter of the poppet seat 188 exposed to reservoir pressure prior to crack remains constant although the conical seat may creep, as the sealing surface, facing reservoir pressure, is parallel to the axis of poppet movement.
  • the conical seat is attached to the poppet housing 178 rather than the poppet body 172 while all hard (poppet) parts are made concentric and perpendicular.
  • all hard (poppet) parts are made concentric and perpendicular.
  • irregularities in the seat 188 or soft part will creep to conform to hard parts.
  • the hard parts are free to rotate but will still conform to the existing soft part deformation.
  • the seal 206 used with the back up ring 204 may be a low friction seal.
  • this seal is pressurized only after cracking due to the poppet body being pressurized internally before cracking, seal friction is greatly minimized.
  • the poppet body begins to move during opening before this seal is pressurized. Thus, breakway friction is not increased by gas pressure.
  • the poppet and regulation valves can act as a low pressure regulator.
  • a cannula 176 is attached to and extends back from a drive piston 212 in front of the poppet valve 170 through the poppet housing 178 and poppet seat 188 and into the back section of the poppet body 172 .
  • Poppet body supply holes 174 extend through the poppet body 172 (Fig. 3).
  • a cannula exhaust hole is provided through the cannula 176 at a position just slightly behind the o-ring 207 which slidably seals the cannula 176 .
  • radially spaced apart drive bores 194 extend through the poppet housing 178 and connect a poppet annulus 198 to the front surface of the poppet housing 178 .
  • the poppet annulus 198 a ring-shaped space, is formed by the inside walls of the poppet housing 178 , the front surface of the poppet 172 and the conical surface of the poppet seat 188 .
  • the front ends of the drive bores 194 are sealed by a preferably rubber disk drive bore seal 196 adhered to the back surface of the drive piston 212 .
  • a joggle 192 in the poppet housing 178 which engages a corresponding lip within the upper housing 42 , acts as a stop for the poppet housing 178 .
  • the reservoir spacer 166 , initiator valve housing 142 , filter ring, shims and the gauge body 106 are then subsequently installed within the upper housing 42 and stack up against the poppet housing 178 , with the end nut 108 clamping these components in place.
  • o-rings 206 slidably seal the poppet body 172 against the poppet housing 178 and poppet nut 180 .
  • the o-rings 206 and back up rings 204 prevent metal to metal contact during movement of the poppet body 172 and also act as pivots and guides to allow slight eccentricity between the poppet body 172 and poppet nut 180 .
  • a ring-shaped plenum 202 is formed between the poppet housing 178 and the drive piston 212 , or the o-ring 214 which slidably seals the drive piston 212 Within the upper housing 42 .
  • the plenum 202 is just wide enough to insure compression on the face seal 195 .
  • a backup ring 218 is provided adjacent to the drive piston seal 214 which is preferably a low friction U-seal.
  • a clap piston 210 is slidably positioned within the drive piston 212 and slidably seals against the drive piston 212 with a clamp piston o-ring 222 .
  • the back surface of the clamp piston 210 and the front vertical wall of the drive piston 212 form a clamp piston plenum 216 (Fig. 3).
  • An o-ring joggle 220 adjacent the back end of the drive piston 212 acts as a stop for the clamp piston o-ring 222 .
  • a clap piston spring 224 within the clamp piston 210 biases forward a jaw plate 228 butting against two opposing flange walls 229 (shown in phantom in Fig. 4) extending from a jaw retainer nut 242 , allowing just enough clearance for the jaws to move freely.
  • the force of the clamp piston spring 224 is accordingly transferred from the plate 228 to the flange walls 229 to the jaw retainer nut 242 and bypasses the clamp jaws 236 .
  • the clamp jaws 236 are biased outwardly or apart and away from each other by a pair of spaced apart jaw springs 238 .
  • the clamp jaws 236 have fine teeth 240 .
  • Each clamp jaw 236 has a planar ramp surface 234 flatly engaged by a corresponding planar ramp drive surface 232 on the forward end of the clamp piston 210 .
  • the jaw retainer nut 242 is threaded into the front end of the drive piston 212 .
  • a return spring 244 is compressed in between the jaw retainer nut 242 and a pressure plate 248 .
  • An indicator ring 250 is rotatably positioned in between the front end of the upper housing 42 and a front collar 252 threaded onto the front end of the upper housing 42 .
  • the indicator ring 250 has colored sections on its outside edge visible through view ports 256 in the front collar 252 , when the indicator ring 250 is turned to a ready to actuate position signifying that the ampule lugs are fully engaged with the injector lugs,
  • a detent pin 288 biased against the back surface of the indicator ring 250 holds the indicator ring in either the ampule loading/unloading position or the ready position, and provides a positive tactile (and optionally an audible click) indication that the ampule is correctly and fully installed, Referring to Fig. 13a, the detent pin 288 slides in or slides against a track 324 cut into the back of the indicator ring.
  • the return spring 244 biases the pressure plate 248 forward, to clamp an ampule behind the lugs 254 on the front collar 252 , and it also acts to return the drive piston after an injection.
  • the indicator ring 250 has three equally spaced apart tuning lugs 258 extending inwardly, for engaging the lugs 382 at the back of an ampule 360 (Fig. 10).
  • the front collar 252 has three equally spaced apart retaining lugs 254 extending radially inwardly, for engaging the front surfaces of the ampule lugs 382 , to hold the ampule into the injector 20 .
  • an actuator link 262 has a forward hook 264 in front of the indicator ring 250 .
  • a rear hook 260 on the actuator link 262 is attached to an actuator slide block 266 slidably mounted in between the upper housing 42 and lower housing 44 .
  • a slide block spring 268 pushing off of the lower housing 44 forwardly biases the actuator slide block 266 .
  • the forward surface of the actuator slide block 266 forms the trigger 30 .
  • an exhaust valve fork 270 extends laterally and upwardly from the actuator slide block 266 to engage a collar on a spool valve 286 .
  • the slide block 266 has a rounded back end 272 facing an initiator valve cam 274 pivotally attached to a holder with a roll pivot pin 278 . Together they are held in a cavity in the upper housing by the upper surface of the lower housing.
  • a gap 280 separates the rounded slide block end 272 and the initiator valve cam 274 (Fig. 3).
  • a set screw 276 threaded into the initiator valve cam 274 engages an initiator pin in the initiator valve 144 .
  • an orifice 282 in the upper housing 42 connects to a drive plenum exhaust bore 284 to continuously vent or bleed the drive plenum 202 to ambient pressure.
  • the orifice has an approximately 0.10 mm diameter opening.
  • the spool valve 286 attached to the exhaust valve fork 270 is slidably positioned within a spool housing 294 secured within an exhaust passage 296 in the upper housing 42 .
  • the spool valve 286 fits within a spool bore 302 in the spool housing 294 with a very close tolerance. While the spool valve 286 does not absolutely seal against the spool bore 302 , leakage between them is very low.
  • a reservoir exhaust bore 290 links the reservoir 168 to a spool valve plenum 300 around the spool valve 286 .
  • a spool valve hole 301 leads from the spool valve plenum 300 to an exhaust duct 304 behind the spool valve 286 .
  • O-rings 292 are positioned on either side of the spool valve plenum 300 to seal the stationary spool valve housing 294 around the reservoir exhaust bore 290 .
  • Muffler seals 306 seal the forward end of the spool valve housing 294 against a muffler tube 308 filled with fiberglass wool 310 or other acoustic material and leading to an exhaust port 316 open to ambient pressure.
  • a muffler retainer 312 and set screw 314 secure the spool valve housing 294 , muffler seals 306 and muffler tube 308 within the exhaust passage 296 .
  • the initiator valve 144 has an initiator valve pin 330 extending from a pin socket 332 .
  • a socket spring 334 overlying the pin socket 332 biases the initiator valve pin 330 outwardly or downwardly into engagement with the set screw 276 in the initiator valve cam 274 .
  • a valve stem 336 spaced slightly apart from the pin socket 332 has a stem collar 342 with a rubber seat ring 340 sealably engaging a seat neck 350 , within an upper chamber 344 of the initiator valve 144 .
  • a stem collar spring 346 positioned in between a valve nut 348 and the stem collar 342 biases the seat ring 340 into engagement with the seat nut 350 to maintain the valve 144 in a closed position.
  • the seat nut 350 is supported by, or part of a valve seat 352 sealed within the initiator valve chamber 146 by an o-ring 338 .
  • the housing is a single piece housing 303 , rather than the two-piece housing shown in Fig. 2.
  • FIG. 6b An alternative preferred design to the exhaust valve shown in Fig. 6 is illustrated in Fig. 6b wherein a valve stem 291 slides inside of a front seal 293 and a rear seal 295 .
  • a seal spacer 297 separates the front seal 293 and the rear seal 295 .
  • the rear end of the valve stem 291 has two narrow slots 305 which provide a channel for flow of gas when the valve is opened, while giving support to the pressurized rear seal 295 to prevent it from collapsing inwardly,
  • the slots 305 form a gradual angle with the rear seal 295 to prevent it from catching on an abrupt edge which could damage the seal.
  • valve stem 291 When actuated, the valve stem 291 is pushed forward and the front edge of the valve slots 305 moves forward to the forward edge of the rear seal 295 .
  • This allows pressurized exhaust gas to flow from an inlet port 307 , through the seal spacer 297 , out of the valve slots 305 , through a muffler 309 and into an outlet port 311 .
  • the front and rear seals 293 and 295 are both u-cup type seals to provide for low friction.
  • the exhaust valve is virtually gas tight and requires very little force for actuation. The only significant force that is translated to the valve stem is after opening, the stem is forced to open further which assists in returning the actuator of the injector.
  • Fig. 6c shows a piston plenum shut-off valve 321 used in the housing 303 , as an alternative to the continuously venting orifice 282 and drive plenum exhaust bore 284 shown in Fig. 6.
  • Shut-off valve 321 includes a piston 323 which has a filter 325 , an orifice 327 and a seal 329 .
  • the piston 323 is biased upwardly and into an open position via a spring 331 .
  • the force keeping the piston 323 down against the seal is provided by the pressure acting on the area of the annulus created by the piston seal 329 and the shut-off seal 333 .
  • the shut-off seal 333 is supported by a valve base 335 which has a vent 337 beneath the shut-off seal 333 to prevent seal escape. Passageways 339 are provided for venting gas.
  • the pressure acting on the valve is reduced, the piston 323 moves away from the shut-off seal 333 due to force provided by a spring 331 , and gas flows freely through the filter 325 , the orifice 327 , and through the passages 339 in the valve base 335 .
  • Figs. 7a and 7b show an alternate preferred embodiment initiator valve 145 (illustrated in the closed position).
  • the initiator valve 145 includes an initiator valve body 147 having an inlet 149 and an outlet 151 .
  • a valve poppet 153 is biased against a valve seat 155 by a spring 157 .
  • the valve seat 155 is preferably ethylene-propylene which resists absorption by carbon dioxide.
  • a valve seat retainer 159 supports the valve seat 155 .
  • a valve stem 169 passes through a valve stem guide 161 and a valve stem seal 163 .
  • a valve stem spring 165 biases the valve stem into a closed position.
  • a valve stem seal 167 slidably seals the valve stem against the valve stem guide 161 .
  • an ampule 360 has three spaced apart lugs 382 at its back end.
  • a flare 380 leads into an ampule chamber 384 to guide a contoured end 364 of a plunger 362 to engage the ampule 360 .
  • the plunger shaft 372 has a cruciform cross section to provide a high moment of inertia using minimum material for the disposable plunger and ampule.
  • a collar 374 on the plunger 362 is spaced apart from the tip of the contoured end 364 so that the collar 374 contacts the back surface 388 of the ampule 360 just before the contoured end 364 of the plunger 362 reaches the front end of the ampule 360 . This prevents the contoured end 364 from colliding with the front end of the ampule 360 and overstressing the ampule or buckling the plunger shaft 372 .
  • Webs 376 extending from the plunger shaft 372 support the collar 374 .
  • the back section 390 of the plunger shaft 372 may have teeth or ridges 378 matching the teeth or ridges 240 on the inside surfaces of the clap jaws 236 , a smooth back section 390 is preferred to avoid variations.
  • the cartridge 54 is loaded into the injector 20 by removing or unsnapping the plastic cartridge chamber cover 56 , placing the cartridge 54 into the cartridge chamber 50 , with the neck of the cartridge 54 facing the piercing point 68 , and then replacing the cartridge chamber cover 56 .
  • the cartridge chamber cover 56 snaps into position on the lower housing 44 .
  • a wavy brass liner 32 say be provided in the cartridge chamber 50 to increase thermal conductivity between the cartridge 54 and the injector 20 .
  • the flip handle 80 on the knob 78 is flipped outwardly so that the knob 78 can be more easily tuned.
  • the knob 78 is turned by hand causing the threaded shaft 72 to advance forwardly and drive the piercing body 66 and housing 58 towards the cartridge 54 .
  • the seal 64 engages and seals against a perimeter on the flat end surface of the cartridge 54 .
  • the piercing point 68 engages and pierces the cartridge seal. Compressed gas from the cartridge 54 flows through the bore 70 , into the annulus 62 , through the hole 92 and moves through the bore 96 into the gauge chamber 122 .
  • the seal 64 prevents leakage of compressed gas into the cartridge chamber 50 which remains at ambient pressure.
  • the cartridge seat 52 supports the cartridge 54 longitudinally against the force exerted by the seal 64 and piercing pin 68 .
  • O-rings 60 , 88 and 94 prevent leakage from the passageways from the cartridge 54 to the gauge chamber 122 .
  • the knob 78 moves forward towards the piercing housing nut 76 .
  • the piercing body 66 and housing are in a fully forward position and the back surface of the knob 78 is approximately flush with the back surface of the upper housing 42 .
  • Compressed gas fills the gauge chamber 122 , passes through the filters 130 and 132 , flows through the port 148 (Fig. 3) and into the upper chamber 344 of the initiator valve 144 (Fig. 7).
  • the stem collar spring 346 biases the seat ring 340 on the stem collar 342 against the seat neck 350 , thereby sealing the upper chamber 344 and preventing the compressed gas from moving forward.
  • the cartridge 54 contains a saturated propellant gas, such as CO 2 , in both liquid and gas states, at temperatures near room temperature.
  • a saturated propellant gas such as CO 2
  • the filters 130 and 132 substantially prevent any liquid from the cartridge 54 from passing. This allows the device to be used in any orientation without affecting injection characteristics. Without the filters, liquid CO 2 could pass into the initiator valve 144 and reservoir 168 and flash into gas during actuation of the injector 20 , causing unpredictable injection characteristics.
  • the Bourdon tube 116 which opens into the gauge chamber 122 is also pressurized, The pressure within the Bourdon tube 116 causes it to spiral outwardly resulting in movement of the pointer 102 to indicate the gas pressure on the gauge label 104 (after the gauge body 106 and gauge base 114 have been properly calibrated), The user can then check the available gas pressure within the injector 20 by looking at the pointer 102 through the lens 98 , as shown in Fig. 8.
  • the ampule 360 , plunger 362 and a filling needle may be provided in a sterile package.
  • the filling needle has a fitting to engage the Luer fitting 392 on the ampule.
  • the ampule may be filled in the same way as a conventional needle and syringe, The filling needle is inserted into a vial of injectant and the injectant is drawn up into the ampule by pulling back on the plunger. Dosage is read by the alignment of the red o-ring 366 with volume graduations on the transparent ampule. The filling needle is removed and safely discarded.
  • the ampule is then ready to be placed into the injector, Variable dosage injections are accordingly achieved by loading the ampule in the same manner as for a needle and syringe,
  • the present injector 20 can inject various dosages without adjusting the injector.
  • the ampule 360 may be filled to e.g., 1/3, 1/2, 3/4, etc. of its full volume capacity, Referring to Fig. 10, loading the ampule 360 with differing volumes of injectant will cause the plunger 362 to extend from the ampule 360 by varying amounts.
  • the injector 20 can successfully drive the plunger 362 from any plunger starting position, a single size ampule 360 can be used for various dosage injections. Ampules of varying volumes are not required.
  • the plunger and ampule are installed into the injector 20 .
  • the lugs 382 on the ampule 360 are aligned to pass through the lugs 254 on the front collar 252 .
  • the back end of the plunger 362 is passed Through the front collar 252 , through the return spring 44 and through the clamp piston spring 224 . Since the teeth or ridges 378 on the plunger 362 extend continuously in between the webs 376 and the back end of the plunger, regardless of the dosage carried by the ampule 360 , the teeth 240 of the clamp jaws 236 will over lie the plunger 362 .
  • the back surface 388 of the ampule 360 comes to rest against the pressure plate 248 .
  • the lugs 382 on the ampule 360 fit in between the lugs 258 on the indicator ring 250 .
  • the user then turns the ampule (clockwise as viewed from the front) through an acute angle e.g., approximately 45°, from an ampule loading position to an ampule ready position.
  • the ampule causes the indicator ring 250 to turn with it as the sides of the ampule lugs 382 push against the sides of the indicator ring lugs 258 .
  • a step on each ampule lug prevents the indicator ring and ampule from being turned beyond range.
  • the track on which the detent pin 288 acts is deep enough that the detent cannot be forced out of the track.
  • the two ends of the track act as detent stops.
  • the indicator ring 250 turns and locks into an injection ready position (Fig. 2a)
  • the colored or painted sections on the outside perimeter of the indicator ring 250 moves into view through the view ports 256 . This indicates to the user that the ampule is properly installed in the injector 20 and ready for injection.
  • a cut out 320 in the indicator ring moves into alignment with the hook 264 on the actuator link 262 .
  • the trigger 30 can then be pulled back to actuate the injector 20 to provide an injection to a patient.
  • the actuator link 262 prevents the trigger 30 from moving to actuate the device. Therefore, the injector 20 cannot be actuated unless an ampule is properly installed and aligned in the ready position.
  • the nozzle 386 of the ampule 360 is placed against the patient's skin and the trigger 30 on the actuator slide block 266 is pulled back by the user's index finger.
  • the exhaust valve fork 270 slides the spool valve 286 from an open position (which allows the reservoir 168 to bleed or exhaust through the exhaust bore to ambient) to a closed position wherein the spool valve 286 substantially seals off the reservoir exhaust bore 290 .
  • the reservoir 168 is accordingly sealed off before the slide block end 272 engages the initiator valve cam 274 .
  • the spool valve serves as an exhaust control valve.
  • the slide block end 272 pushes against the initiator valve cam 274 levering the set screw 276 against the initiator valve pin 330 .
  • the sliding movement of the trigger performs three functions: It controls the initiator valve, it controls the spool valve, and it provides an interlock when disabled by the actuator link 262 .
  • the set screw 276 pushes up on the initiator valve pin 330 .
  • the pin socket 332 is driven up against the valve stem 336 causing the stem collar to shift upwardly and separate the seat ring 340 from the seat neck 350 , thereby opening the initiator valve 144 .
  • the valve poppet spring 157 biases the valve poppet 153 toward the valve seat 155 . Gas pressure from the gas inlet 149 drives the poppet 153 into the valve seat 155 creating a gas tight meal.
  • the valve seat 155 is vented on the bottom side 171 to prevent the seat from escaping from the groove 173 .
  • the valve seat retainer 159 retains and vents the valve seal 155 .
  • the valve stem 169 is mechanically isolated from the poppet 153 to assure that the poppet closes without interference from the stem.
  • valve stem 169 slides up and contacts the valve poppet 153 , pushing it away from the valve seat 155 .
  • valve stem spring 165 returns the valve stem to the neutral position and the valve poppet 153 also returns to the closed position.
  • compressed gas flows from the cartridge 54 through the filters and initiator valve 144 , through the reservoir port 154 past the dart 160 and into the reservoir 168 .
  • gas pressure also builds within the poppet chamber 208 , as gas flows from the reservoir 168 through the poppet body supply holes 174 .
  • the clamp piston 210 is driven forward compressing the clamp piston spring 224 and driving the clamp jaws 236 together, through the interaction of the ramp drive 232 on the clamp piston 210 and the clamp piston ramps 234 on the clamp jaws 236 .
  • the teeth 240 on the clamp jaws 236 clamp down and around the plunger 362 .
  • the clamp jaws 236 and their driving mechanism perform two functions: They grab onto the plunger at whatever position the plunger is in, and they transfer driving force from the drive piston to the plunger.
  • the plunger 362 will be fully extended to the rear such that the clamp jaws 236 will engage the plunger 362 close behind the webs 376 .
  • the plunger 362 will extend a shorter distance behind the ampule 360 and the clamp jaws 236 will engage the plunger 362 towards the back end of the plunger.
  • the clamp jaws 236 securely clamp and engage the plunger 362 with the teeth 240 on the clamp jaws 236 locked into the teeth 378 on the plunger 362 .
  • the gas pressure in the clamp piston plenum 216 maintains the engagement of the clamp jaws 236 to the plunger 362 during the injection sequence. As represented in Fig. 12, the clap jaws clap onto the plunger before the poppet valve opens.
  • pressure in the poppet chamber 208 continues to build until it is sufficient to crack the poppet valve 170 open.
  • the poppet spring chamber 226 is sealed from the reservoir 168 and the poppet chamber 208 and is vented to ambient pressure.
  • the rearward acting force resulting from the gas pressure acting on the incline surfaces 152 of the poppet body 172 will exceed the forward acting force of the poppet spring 186 .
  • this "cracking point" is reached, the poppet valve 170 snaps open.
  • the poppet body 172 shifts or slides rearwardly,
  • the sealing edge surface 200 separates from its sealing engagement against the conical poppet seat 188 allowing gas from the reservoir 168 to flow through the poppet chamber 208 to the drive bores 194 .
  • the poppet valve 170 begins to open and the poppet body 172 moves away from the conical poppet seal 188 , the annular front surface 230 of the poppet body 172 is acted on by gas pressure now in the poppet annulus 198 . Since the surface areas acted on by the compressed gas are vastly increased with the addition of the front surface 230 of the poppet body, the force acting on the poppet body 172 rapidly escalates.
  • the poppet valve 170 therefore opens with an "over-center" or hard-over action.
  • the regulation valve 156 closes down via the dart 160 engaging and sealing against the regulation seat 158 .
  • additional gas supply to the reservoir 168 is, at least initially, restricted by the regulation valve 156 , with substantially only the reservoir 168 then acting as a source of compressed gas.
  • pressure regulation of the reservoir is provided through poppet area ratios and spring forces (which may be readily determined for various capacity injectors by those skilled in the art).
  • the reservoir pressure reaches a desired minimum pressure.
  • the drive piston plenum has been supplied by a fixed supply of gas from the reservoir.
  • the spring force acting forwardly on the poppet body, overcomes the net pressure force, acting rearwardly on the poppet body.
  • the poppet body moves forward, lessening the regulation valve restriction to incoming flow.
  • the dart 160 moves with the poppet body away from the seat 158 to allow commencement or increase of gas flow.
  • the opening of the regulator valve consequently increases gas flow into the reservoir and increases the reservoir pressure.
  • the poppet body again moves rearwardly to restrict the incoming flow,
  • the poppet valve and regulator valve act together as a reservoir pressure regulator (and consequently drive piston plenum pressure and ampule pressure).
  • regulation movement when present, occurs generally during the last half of the injection.
  • the CO 2 cartridge is filled with saturated CO 2 .
  • the peak ampule pressure is determined by the poppet valve cracking pressure which is independent of source pressure.
  • the minimum delivery pressure, governed by the pressure regulation is also independent of source pressure. Both of these features are controlled by area ratios and spring rates.
  • the injector is substantially temperature independent.
  • Fig. 12 illustrates the effect of pressure regulation.
  • a smaller dosage of e.g., 1/2 ml or less generally there is no pressure regulation.
  • larger dosages of e.g., over 3/4 ml pressure regulation occurs.
  • intermediate range dosages of e.g., between 1/2 and 3/4 ml some pressure regulation may occur.
  • the rubber or elastomeric face seal 196 adhered to the back of the drive piston 212 assists to rapidly open the poppet valve 170 .
  • the face seal 196 encourages the build up of pressure in the drive bores 194 and poppet annulus 198 before pressurizing the drive plenum 202 . Accordingly, the rapid pressure increase within the drive bores 194 and poppet annulus 198 shorten the time required for opening the poppet valve 170 providing a quick ampule pressure rise time and a more uniform ampule peak pressure.
  • the poppet body supply holes 174 have a large diameter to minimize pressure drop from the reservoir 168 to the poppet chamber 208 .
  • the trigger 30 is held back for longer than necessary for the injection, only a small amount of gas is wasted since all spaces within the injector, except the drive plenum, remain virtually sealed while the trigger is held back.
  • the drive plenum is opened to ambient pressure, but only through orifice 282 which severely restricts flow.
  • the regulation valve 156 restricts flow while the trigger is held back.
  • the trigger is released.
  • the slide block spring 268 assisted by exhaust gas pressure returns the slide block 266 to its forward position.
  • the initiator valve then closes, Then the exhaust valve fork 270 moving with the slide block 266 pulls the spool valve 286 forward reconnecting the spool valve bore 302 and spool plenum 300 to the reservoir exhaust bore 290 .
  • the spool valve and exhaust passage allow the injector to be quickly and quietly reset for another injection, Gas in the reservoir exhausts out through the reservoir exhaust bore 290 and exhaust passage 296 .
  • the exhaust gas pressure in the exhaust passage 296 pushes on the back of the spool valve 286 and helps to return the spool valve and slide block forward to their original ready positions.
  • the slide block spring 268 consequently need only exert a slight force, thereby helping to reduce the finger force necessary to pull the trigger 30 .
  • the drive piston 212 is in the forward position (Fig. 2c), with the plunger shoulder in contact with and exerting a large force on the back end 388 of the ampule 360 .
  • the drive piston return spring 244 , clamp piston spring 224 and jaw springs 238 are compressed.
  • the jaws 236 are engaged with the plunger and the clamp piston 210 is forward. Each part must then return to the ready position.
  • the reservoir 168 Upon release of the trigger 30 , the reservoir 168 is able to rapidly vent to atmosphere.
  • Drive piston plenum gas vents into the reservoir, in part, through the poppet body, until the poppet valve closes, Gas also vents into the reservoir through the cannula 176 , until the holes in the cannula are sealed by the o-ring 190 contained within the poppet seat 188 .
  • This remaining gas which occupies a relatively small volume, and is at a very low pressure, vents through the bleed orifice 282 connecting the drive piston plenum directly to the atmosphere through the drive plenum exhaust bore 284 . Since the orifice 282 is always open, even during the injection, some beneficial drive gas is lost, thus it is a very small, restrictive orifice. Because the orifice 282 is small, if it was the only vent for drive piston plenum gas (i.e., if there were no cannula side holes), venting and reset time would be unacceptably long.
  • the following reset sequence occurs and is controlled by component areas and spring forces, which may be readily determined by those skilled in the art.
  • the clap jaws 236 and clap piston 210 release. This must occur before the drive piston is released so that the plunger is not pulled back.
  • the clamp piston spring force overcomes the opposing pressure force. This release occurs when the drive piston 212 is close to a force equilibrium condition. The pressure force must be close to the opposing spring force. If not, then the drive piston 212 will rapidly return (if the spring force is larger) or plunge forward (if pressure force is larger) causing noise and possible damage to the injector, Thus a force balance is established at the point of plunger release, regardless of the dosage.
  • the drive piston 212 After the plunger release, the drive piston 212 returns as the reservoir bleeds. The drive piston 212 is forced rearward by the drive piston return spring against the opposing pressure force. Gas exhaust and reset occurs quietly and quickly.
  • O-ring 222 serves as a seal and a bumper to quiet the clamp piston return.
  • the plunger 362 is driven forward until the collar 374 contacts the back surface 388 of the ampule 360 . Accordingly, if the trigger 30 is squeezed once and an injection given, released and squeezed again after some delay (i.e., "second fire") without replacing the ampule, the jaws will grab the plunger with the plunger collar in the forward most position, i.e., in contact with the rear ampule face. Thus no forward movement of the drive piston will occur. A second fire does not damage the ampule, plunger or injector.
  • the cannula 176 is attached to and moves with the drive piston 212 .
  • the cannula exhaust hole 190 in the cannula 176 speeds the return stroke of the piston 212 .
  • the poppet valve closes before the drive piston begins its return, Thus a bleed hole in the cannula is required for gas to flow from the drive piston plenum to the reservoir.
  • gas in the drive plenum 202 flows through the cannula exhaust hole 190 through the cannula 176 , back into the reservoir 168 and out through the relatively unobstructed exhaust system of the reservoir exhaust bore 290 and the exhaust passage 296 .
  • the spent ampule and plunger are turned and removed from the injector 20 which is then prepared for the next injection sequence.
  • the ampule and plunger are preferably a single use disposable unit.
  • the plunger may have tapered sections at the front or back which engage a generally complimentary tapered section in the ampule.
  • the injector exerts hundreds of pounds of force on the plunger which drives the tapered section of the plunger of Figs. 10a and 10b into an interference fit with the tapered section of the ampule.
  • the used and non sterile plunger and ampule cannot easily then be re-used.
  • the tapered sections can also act as a plunger stop, in place of the collar on the plunger of Fig. 10, The taper on the plunger and ampule are slightly mismatched and lock together only with high forces (at the end of an injection) and not at low forces (during filling of the ampule).
  • Fig. 10c shows another non-reusable ampule and plunger having a detent. The detent is dimensioned so that only a large force will cause engagement.
  • the injector can be modified to give multiple sequential injections to the same patient.
  • a drive piston stop 394 is added, and acts to stop the drive piston, as the plunger shoulder does in variable delivery.
  • the jaws then disengage and the injector resets.
  • the plunger will automatically be in a "ready” position for the next shot, and the injector may be fired again to deliver the same small dosage.
  • This sequence may be repeated to deliver several small dosage injections until the plunger shoulder contacts the ampule. Dosage may be adjusted by rotating the outer ring 396 to the desired value, indicated by graduations 398 on the injector housing. A longer ampule can be provided to allow for more sequential shots.
  • the present method of needleless injection uses a system of an injector and compatible ampules.
  • the injector is designed to apply a specific force on the plunger of the ampules.
  • the force applied to the plunger by the injector is varied, forming a force - displacement curve.
  • the force applied to the plunger is quite high.
  • the applied force is reduced substantially linearly until the volume injected reaches approximately 0.5 ml, and thereafter the force is held substantially constant.
  • This force displacement curve is independent of the ampule nozzle size.
  • This force - displacement curve translates directly to an ampule pressure - volume injected curve.
  • the injection system employs a singular pressure profile and a family of ampules with various orifice sizes to achieve various depths of penetration.
  • Fig. 17 shows preferred uses of various diameter nozzles with the pressure profile described below.
  • the preferred pressure profile has the following properties: First the pressure rapidly increases from 0 to a value of about 26900-29670 kPa, and preferably about 28290 kPa, (4100 psi) in less than 6 milliseconds (and preferably less than 1 ms). This quick pressure rise avoids "splash-back" and loss of injectant. This pressure range is sufficient to pierce the tissues, but not so high as to cause the excessive pain associated with higher pressures. The pressure is gradually reduced to approximately 8280 - 13800 kPa, and preferably 12420 kPa, (1800 psi) in a generally linear (pressure - volume) fashion corresponding with volume discharged of 0.5 ml.
  • the curve forms an exponential decay.
  • the pressure is held constant until the end of the injection, at which time the pressure abruptly goes to 0 within 5 ms.
  • Final pressures below about 8280 kPa tend to result in "leak-back" of the injectant after the injection,
  • the pressure profile is defined as the pressure immediately proximal to the nozzle.
  • the above- described pressure profile covers an injection larger than approximately 0.5 ml. If the injection is less than this amount, the pressure - profile curve is simply truncated at the end of the delivered volume.
  • Medication viscosity affects penetration of intramuscular injections in a direction contrary to prior art.
  • Experimental data shows that more viscous medications, in the range of from 0.01 to 0.70 poise, have greater fascia penetrating capability, apparently because of reduced turbulence and lower Reynold's number.
  • the present invention also includes the appropriate guidelines for selection of nozzle size with viscous medications.
  • Viscous medications preferably use the same size orifice as for water based medications. Nearly all viscous medications are intramuscular injections, Testing shows that viscous medications have more energy to penetrate the deep fascia than water based medications, but do not go substantially deeper into the muscle. Therefore, the deposition into the muscle is comparable independent of medication viscosity.
  • the present peri-fascial injection is provided by using a nozzle diameter which is smaller than that which would ordinarily be used for an intramuscular injection.
  • the peri-fascial injection is provided by using a SC nozzle (0.10 mm) at an IM injection site preferably with less than 5 mm adipose. This works well because IM sites tend to have very thin layers of adipose tissue.
  • the SC nozzle has sufficient penetrating energy to deposit the medication on the deep fascia when injected into a thin layer of adipose.
  • a peri-fascial injection can also be given at an IM injection site having a 10-15 mm adipose layer using a 0.15 mm diameter nozzle and the above-described pressure profile.
  • the injectant 800 in a peri-fascial injection bores through the skin 802 and adipose 804 , but not the fascia 806 . Rather, the injectant forms a thin layer 808 over the fascia, The thin layer 808 may provide the same pharmacological effect as an IM injection, without penetrating the muscle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (5)

  1. Verfahren zum Liefern eines Einspritzstrahls durch unter Druck setzen eines fluiden Injektats innerhalb einer Ampulle (360), welches Verfahren die Schritte aufweist:
    einen Tauchkolben (362) mit ausreichender Kraft in eine Ampulle (360) treiben, so daß innerhalb von 6 Millisekunden ein Druck von 26000-30000 kPa erzeugt wird;
    den Druck im allgemeinen linear reduzieren, bis 0,5 ml herausgetrieben werden und der Druck 8000-14000 kPa beträgt;
    den Druck so lange bei 8000-14000 kPa halten, bis ein gewünschtes Volumen an Injektat aus der Ampulle (360) herausgetrieben worden ist; und
    den Druck innerhalb von 5.0 Millisekunden auf ungefähr 0.0 kPa reduzieren.
  2. Verfahren gemäß Anspruch 1, welches weiter den Schritt des Regulierens des Durchmessers der Mündungsöffnung der Ampulle (360) aufweist.
  3. Verfahren gemäß Anspruch 1 oder 2, welches weiter den Schritt des Regulierens der Viskosität des Injektats aufweist.
  4. Verfahren gemäß Anspruch 3, wobei die Viskosität des Injektats im Bereich von 0,01 bis 0,70 Poise liegt.
  5. Verfahren gemäß einem der Ansprüche 1-4, welches weiter den Schritt des Filterns des komprimierten Gases, bevor es in ein Reservoir abgelassen wird, aufweist.
EP93918344A 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen Expired - Lifetime EP0651663B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/920,106 US5383851A (en) 1992-07-24 1992-07-24 Needleless hypodermic injection device
US920106 1992-07-24
PCT/US1993/006940 WO1994002188A1 (en) 1992-07-24 1993-07-23 Needleless hypodermic injection methods and device

Publications (3)

Publication Number Publication Date
EP0651663A1 EP0651663A1 (de) 1995-05-10
EP0651663A4 EP0651663A4 (de) 1995-08-30
EP0651663B1 true EP0651663B1 (de) 1999-12-01

Family

ID=25443171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93918344A Expired - Lifetime EP0651663B1 (de) 1992-07-24 1993-07-23 Verfahren für nadellose subkutaninjektionen

Country Status (8)

Country Link
US (3) US5383851A (de)
EP (1) EP0651663B1 (de)
JP (2) JP3633615B2 (de)
AT (1) ATE187083T1 (de)
AU (1) AU676490B2 (de)
CA (1) CA2140772C (de)
DE (1) DE69327165T2 (de)
WO (1) WO1994002188A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor

Families Citing this family (1170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2689017B1 (fr) * 1992-03-31 1994-05-27 Mtc Medical Appareil d'injection medicale ou veterinaire.
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5405333A (en) * 1992-12-28 1995-04-11 Richmond; Frank M. Liquid medicament bag with needleless connector fitting using boat assembly
US6206860B1 (en) 1993-07-28 2001-03-27 Frank M. Richmond Spikeless connection and drip chamber with valve
US5540657A (en) * 1994-07-15 1996-07-30 Collagen Corporation Delivery device for injectable materials
DE19519279A1 (de) * 1994-12-07 1996-08-22 Wolfgang Dr Med Wagner Verfahren und Einrichtung zur Saug-Druckinjektion
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
DE29507987U1 (de) * 1995-05-15 1996-09-19 Ferton Holding, Delemont Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US5893397A (en) * 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5722953A (en) 1996-02-29 1998-03-03 Medi-Ject Corporation Nozzle assembly for injection device
US5697917A (en) 1996-02-29 1997-12-16 Medi-Ject Corporation Nozzle assembly with adjustable plunger travel gap
US5800388A (en) 1996-02-29 1998-09-01 Medi-Ject Corporation Plunger/ram assembly adapted for a fluid injector
US5865795A (en) 1996-02-29 1999-02-02 Medi-Ject Corporation Safety mechanism for injection devices
US5643211A (en) 1996-02-29 1997-07-01 Medi-Ject Corporation Nozzle assembly having a frangible plunger
US5921967A (en) 1996-02-29 1999-07-13 Medi-Ject Corporation Plunger for nozzle assembly
US5785688A (en) * 1996-05-07 1998-07-28 Ceramatec, Inc. Fluid delivery apparatus and method
BR9710025A (pt) * 1996-07-01 1999-08-10 Pharmacia & Upjohn Ab Dispositivo de distribuição de preparação processo para operar o mesmo sistema de recipientes de medicamento receipiente do tipo de cartucho de seringa sistema de marcação de leitura por máquina e dispositivo para análise de um objeto
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6106502A (en) * 1996-12-18 2000-08-22 Richmond; Frank M. IV sets with needleless fittings and valves
US5875976A (en) 1996-12-24 1999-03-02 Medi-Ject Corporation Locking mechanism for nozzle assembly
US5993412A (en) * 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US5911703A (en) * 1997-05-22 1999-06-15 Avant Drug Delivery Systems, Inc. Two-stage fluid medicament jet injector
US5947928A (en) * 1997-06-19 1999-09-07 Mile Creek Capital, Llc Drug delivery system
USD399951S (en) 1997-06-30 1998-10-20 Bioject, Inc. Injection apparatus
US5964735A (en) * 1997-07-01 1999-10-12 Medisys Technologies, Inc. Fine needle aspiration safety syringe
EP0888790A1 (de) * 1997-07-04 1999-01-07 PowderJect Research Limited Vorrichtung zur Abgabe von Medikamententeilchen
US6569127B1 (en) * 1997-07-18 2003-05-27 Liebel-Flarsheim Company Adapter and syringe for front-loading medical fluid injector
US6171276B1 (en) 1997-08-06 2001-01-09 Pharmacia & Upjohn Ab Automated delivery device and method for its operation
US6071272A (en) * 1997-10-28 2000-06-06 Hoffman; Alan S. Method for treating erectile dysfunctionality
US6610042B2 (en) 1997-12-05 2003-08-26 Felton Medical, Inc. Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US5993418A (en) * 1998-02-24 1999-11-30 Medisys Technologies, Inc. Safety syringe
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2002511396A (ja) 1998-04-14 2002-04-16 メルク エンド カムパニー インコーポレーテッド ポリヌクレオチド製剤の無針投与
AU5230299A (en) 1998-07-27 2000-02-21 Becton Dickinson & Company Injection-assisting probe for medical injector assembly
US6123684A (en) * 1998-07-27 2000-09-26 Medi-Ject Corporation Loading mechanism for medical injector assembly
GB9818110D0 (en) * 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
CN1315877A (zh) 1998-08-31 2001-10-03 强生消费者公司 含刀片的电传送装置
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6783509B1 (en) 1998-11-18 2004-08-31 Bioject Inc. Single-use needle-less hypodermic jet injection apparatus and method
US6383168B1 (en) 1998-12-08 2002-05-07 Bioject Medical Technologies Inc. Needleless syringe with prefilled cartridge
US6132395A (en) * 1998-12-08 2000-10-17 Bioject, Inc. Needleless syringe with prefilled cartridge
US6406455B1 (en) * 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
DE19859137C1 (de) * 1998-12-21 2000-05-18 Ferton Holding Sa Ejektionsgerät zur Hochdruckejektion einer Flüssigkeit
US6849060B1 (en) 1999-01-29 2005-02-01 Powderject Research Limited Particle delivery device
US6328714B1 (en) 1999-01-29 2001-12-11 Powderject Research Limited Particle delivery device
AU4239300A (en) 1999-04-16 2000-11-02 Johnson & Johnson Consumer Companies, Inc. Electrotransport delivery system comprising internal sensors
US7060048B1 (en) * 1999-04-16 2006-06-13 Powerject Research Limited Needleless syringe
WO2000064514A1 (en) * 1999-04-22 2000-11-02 Gilbert Garitano Needleless permanent makeup and tattoo device
US6689103B1 (en) 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US6319230B1 (en) 1999-05-07 2001-11-20 Scimed Life Systems, Inc. Lateral needle injection apparatus and method
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
AU5595300A (en) * 1999-06-02 2000-12-18 Microheart, Inc. Devices and methods for delivering a drug
US7147633B2 (en) * 1999-06-02 2006-12-12 Boston Scientific Scimed, Inc. Method and apparatus for treatment of atrial fibrillation
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
US6890553B1 (en) 1999-07-08 2005-05-10 Johnson & Johnson Consumer Companies, Inc. Exothermic topical delivery device
US6319224B1 (en) * 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
AU7064700A (en) * 1999-08-20 2001-03-19 Bioject, Inc. Intramuscular injection system for injecting dna-based injectables into humans
US20050027239A1 (en) * 1999-08-20 2005-02-03 Stout Richard R. Intradermal injection system for injecting DNA-based injectables into humans
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7113821B1 (en) 1999-08-25 2006-09-26 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery
US7133717B2 (en) * 1999-08-25 2006-11-07 Johnson & Johnson Consumer Companies, Inc. Tissue electroperforation for enhanced drug delivery and diagnostic sampling
CA2387326A1 (en) 1999-10-11 2001-04-19 Needleless Ventures, Inc. Universal anti-infectious protector for needleless injectors
US7074210B2 (en) * 1999-10-11 2006-07-11 Felton International, Inc. Universal protector cap with auto-disable features for needle-free injectors
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6569123B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Prefillable intradermal injector
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US20020198509A1 (en) * 1999-10-14 2002-12-26 Mikszta John A. Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US6776776B2 (en) * 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6770054B1 (en) 1999-11-23 2004-08-03 Felton International, Inc. Injector assembly with driving means and locking means
US7029457B2 (en) * 1999-11-23 2006-04-18 Felton International, Inc. Jet injector with hand piece
WO2001037907A1 (en) * 1999-11-23 2001-05-31 Needleless Ventures, Inc. Injector assembly with driving means and locking means
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
US6344027B1 (en) 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
DE60144229D1 (de) * 2000-01-07 2011-04-28 Valeritas Inc Injektionsvorrichtung
JP5502253B2 (ja) 2000-02-23 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
FR2805749B1 (fr) * 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale Seringue sans aiguille a deux niveaux de vitesse d'injection
US7137968B1 (en) * 2000-03-13 2006-11-21 Nucryst Pharmaceuticals Corp. Transcutaneous medical device dressings and method of use
EP1265663B1 (de) * 2000-03-23 2011-03-02 Antares Pharma, Inc. Einwegdruckstrahlinjektor
US6719987B2 (en) 2000-04-17 2004-04-13 Nucryst Pharmaceuticals Corp. Antimicrobial bioabsorbable materials
US6716190B1 (en) * 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
FR2807946B1 (fr) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
US7404815B2 (en) * 2000-05-01 2008-07-29 Lifescan, Inc. Tissue ablation by shear force for sampling biological fluids and delivering active agents
US6689101B2 (en) * 2000-05-22 2004-02-10 Pharmacia Ab Medical arrangement
US6406456B1 (en) 2000-06-08 2002-06-18 Avant Drug Delivery Systems, Inc. Jet injector
US6645169B1 (en) * 2000-06-08 2003-11-11 Avant Drug Delivery Systems, Inc. Air-in-tip jet injector
DE10029325A1 (de) * 2000-06-20 2002-01-03 Peter Lell Nadellose Injektionsvorrichtung mit pyrotechnischem Antrieb
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7001617B2 (en) 2001-04-23 2006-02-21 Nueryst Pharmaceuticals Corp. Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
ES2231528T3 (es) 2000-07-27 2005-05-16 Nucryst Pharmaceuticals Corp. Utilizacion de metales nobles para la fabricacion de un medicamento para el tratamientyo de trastornos y enfermedades cutaneas hiperproliferativas.
US20030180379A1 (en) * 2000-07-27 2003-09-25 Burrell Robert E. Solutions and aerosols of metal-containing compounds
US6989157B2 (en) * 2000-07-27 2006-01-24 Nucryst Pharmaceuticals Corp. Dry powders of metal-containing compounds
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
US7427416B2 (en) * 2000-07-27 2008-09-23 Nucryst Pharmaceuticals Corp. Methods of treating conditions using metal-containing materials
US7008647B2 (en) 2001-04-23 2006-03-07 Nucryst Pharmaceuticals Corp. Treatment of acne
US20040191329A1 (en) * 2000-07-27 2004-09-30 Burrell Robert E. Compositions and methods of metal-containing materials
US20030185901A1 (en) 2000-07-27 2003-10-02 Burrell Robert E. Methods of treating conditions with a metal-containing material
US20030206966A1 (en) * 2000-07-27 2003-11-06 Burrell Robert E. Methods of inducing apoptosis and modulating metalloproteinases
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CA2324045A1 (fr) * 2000-10-20 2002-04-20 Universite De Sherbrooke Seringue sans aiguille pour l'injection sous-cutanee de poudres medicamenteuses
FR2815544B1 (fr) * 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
US6652483B2 (en) * 2000-11-07 2003-11-25 Avant Drug Delivery Systems, Inc. Needleless jet injector system with separate drug reservoir
US6626863B1 (en) 2000-11-22 2003-09-30 Nusaf, L.L.C. Safety syringe
US7150409B2 (en) * 2000-11-30 2006-12-19 Biovalve Technologies, Inc. Injection systems
WO2002056947A1 (en) * 2001-01-18 2002-07-25 Medrad, Inc. Syringe interfaces and adapters for use with medical injectors
US6758837B2 (en) 2001-02-08 2004-07-06 Pharmacia Ab Liquid delivery device and method of use thereof
DK1361890T3 (da) 2001-02-23 2011-06-27 Glaxosmithkline Biolog Sa Influenzavaccineformuleringer til intradermal indgift
US6471669B2 (en) * 2001-03-05 2002-10-29 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
US6645170B2 (en) * 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20020172615A1 (en) * 2001-03-08 2002-11-21 Archie Woodworth Apparatus for and method of manufacturing a prefilled sterile container
US20020139088A1 (en) 2001-03-08 2002-10-03 Archie Woodworth Polymeric syringe body and stopper
JP2004529754A (ja) 2001-03-14 2004-09-30 ペンジェット・コーポレーション 溶液から溶解ガスを除去するためのシステムおよび方法
ZA200200808B (en) * 2001-03-22 2002-08-12 Roche Diagnostics Gmbh Needleless hypodermic injection system, application device and medication cartridge therefor.
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6613010B2 (en) * 2001-04-13 2003-09-02 Penjet Corporation Modular gas-pressured needle-less injector
US20050192530A1 (en) * 2001-04-13 2005-09-01 Penjet Corporation Method and apparatus for needle-less injection with a degassed fluid
CA2445729C (en) * 2001-04-23 2013-07-02 Nucryst Pharmaceuticals Corp. Use of metals to treat mucosal membranes
WO2002087663A2 (en) 2001-04-27 2002-11-07 Penjet Corporation Method and apparatus for filling or refilling a needle-less injector
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
US6648850B2 (en) * 2001-06-08 2003-11-18 Bioject, Inc. Durable needle-less jet injector apparatus and method
US20060018877A1 (en) * 2001-06-29 2006-01-26 Mikszta John A Intradermal delivery of vacccines and therapeutic agents
US7544188B2 (en) * 2001-07-19 2009-06-09 Intelliject, Inc. Medical injector
US7767872B2 (en) * 2001-09-06 2010-08-03 Mpg Biotechnologies, Llc Thimerosal removal device
US8440791B2 (en) * 2001-09-06 2013-05-14 Mgp Biotechnologies, Llc Thimerosal removal device
US6669664B2 (en) 2001-09-07 2003-12-30 Avant Drug Delivery Systems, Inc. Vacuum control cycle for jet injector
AU2002362368B2 (en) 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
US6824526B2 (en) 2001-10-22 2004-11-30 Penjet Corporation Engine and diffuser for use with a needle-less injector
GB0125506D0 (en) * 2001-10-24 2001-12-12 Weston Medical Ltd Needle free injection method and apparatus
DE60236949D1 (de) * 2001-11-09 2010-08-19 Alza Corp Pneumatisch angetriebener autoinjektor
US6607510B2 (en) 2001-11-09 2003-08-19 Bioject Medical Technologies Inc. Disposable needle-free injection apparatus and method
EP1443992B1 (de) * 2001-11-09 2007-01-03 Alza Corporation Zusammenschiebbarer spritzenbehälter
TWI222370B (en) * 2001-12-14 2004-10-21 Roche Diagnostics Gmbh Needleless hypodermic injection device
EP2224012B1 (de) 2001-12-17 2013-01-30 Corixa Corporation Zusammensetzungen und Verfahren zur Therapie und Diagnose von entzündlicher Darmerkrankung
JP2005518873A (ja) * 2002-03-04 2005-06-30 ナノ パス テクノロジーズ リミテッド 生体障壁を横切る流体輸送の為の装置及び方法
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
JP4594623B2 (ja) 2002-04-12 2010-12-08 シェーリング コーポレイション Ｇタンパク質共役レセプターリガンドおよび方法
BR122017016940B8 (pt) 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
PL210412B1 (pl) 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US7238167B2 (en) * 2002-06-04 2007-07-03 Bioject Inc. Needle-free injection system
US6676630B2 (en) 2002-06-04 2004-01-13 Bioject Medical Technologies, Inc. Needle-free injection system
US7156823B2 (en) * 2002-06-04 2007-01-02 Bioject Inc. High workload needle-free injection system
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US6883222B2 (en) * 2002-10-16 2005-04-26 Bioject Inc. Drug cartridge assembly and method of manufacture
AU2003301445A1 (en) 2002-10-17 2004-05-04 Genmab A/S Human monoclonal antibodies against cd20
WO2004037186A2 (en) * 2002-10-22 2004-05-06 Nucryst Pharmaceuticals Corp. Prophylactic treatment methods
US7018356B2 (en) 2002-10-31 2006-03-28 Wise Roger R Method and apparatus for adjusting the contents of a needle-less injector
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003275895B2 (en) 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
MXPA05007295A (es) 2003-01-06 2005-09-30 Corixa Corp Ciertos compuestos de fosfato de aminoalquil glucosaminida y su uso.
ES2362424T3 (es) 2003-01-07 2011-07-05 Dyax Corporation Biblioteca del dominio kunitz.
SI2441467T1 (sl) 2003-01-31 2015-10-30 The Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
US6935384B2 (en) * 2003-02-19 2005-08-30 Bioject Inc. Needle-free injection system
FR2852517B1 (fr) * 2003-03-21 2005-11-11 Dispositif d'injection sans aiguille a cartouche pyrotechnique et procede d'assemblage d'un tel dispositif
US20060184101A1 (en) * 2003-04-21 2006-08-17 Ravi Srinivasan Microjet devices and methods for drug delivery
MXPA05011246A (es) * 2003-04-21 2006-07-06 Stratagen Life Sciences Inc Metodos y aparatos para la administracion repetitiva de farmacos por microchorro.
MXPA05011406A (es) 2003-04-23 2005-12-12 Medarex Inc Anticuerpos humanizados para el receptor-1 de interferon alfa (ifnar-1).
WO2004110533A1 (ja) * 2003-05-09 2004-12-23 Anges Mg, Inc. 薬剤が収容された針無注射器
AU2004272972A1 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
IL157981A (en) 2003-09-17 2014-01-30 Elcam Medical Agricultural Cooperative Ass Ltd Auto injector
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
EP1685865A4 (de) * 2003-11-21 2009-12-30 Zhongshan Botai Pharmaceutic I Spritze zum vormischen eines pulverförmigen medikaments
HUE026260T2 (en) 2003-11-21 2016-06-28 Ucb Biopharma Sprl A method for treating multiple sclerosis by inhibiting IL-17 activity
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
AU2004299833B2 (en) 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
ES2542139T3 (es) 2004-03-08 2015-07-31 Ichor Medical Systems Inc. Aparato mejorado para el suministro, mediado eléctricamente, de agentes terapéuticos
IL160891A0 (en) 2004-03-16 2004-08-31 Auto-mix needle
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
RU2006138704A (ru) * 2004-05-19 2008-06-27 Вайет (Us) Модуляция производства иммуноглобулина и атопические расстройства
US7717874B2 (en) * 2004-05-28 2010-05-18 Bioject, Inc. Needle-free injection system
PL2662390T3 (pl) 2004-06-21 2017-12-29 E. R. Squibb & Sons, L.L.C. Antyciała receptora interferonu alfa I oraz ich zastosowania
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20060040895A1 (en) * 2004-08-19 2006-02-23 Kipling Thacker Aesthetic use of hyaluronan
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
NZ553775A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition for use in vaccination against staphylococcei
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006052975A2 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
EP1824976A4 (de) 2004-11-12 2008-07-09 Univ British Columbia Antimikrobielle peptide
CN103169965A (zh) 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
CA2791286C (en) * 2004-11-22 2015-09-01 Intelliject, Inc. Devices, systems, and methods for medicament delivery
US10737028B2 (en) 2004-11-22 2020-08-11 Kaleo, Inc. Devices, systems and methods for medicament delivery
US7648483B2 (en) 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems and methods for medicament delivery
US7648482B2 (en) 2004-11-22 2010-01-19 Intelliject, Inc. Devices, systems, and methods for medicament delivery
US11590286B2 (en) 2004-11-22 2023-02-28 Kaleo, Inc. Devices, systems and methods for medicament delivery
US7947017B2 (en) * 2004-11-22 2011-05-24 Intelliject, Inc. Devices, systems and methods for medicament delivery
JP4904283B2 (ja) * 2004-12-01 2012-03-28 アキュショット インク 無針注射器
AU2005311635B2 (en) * 2004-12-03 2012-02-02 Biogen Ma Inc. Delaying or preventing onset of multiple sclerosis
CA2589885A1 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
US7351226B1 (en) * 2004-12-07 2008-04-01 Glenn Herskowitz Medical infusion pump
EP1841866B1 (de) * 2005-01-25 2009-04-22 Sky Genetics, Inc. Nukleinsäuren für die apoptose von krebszellen
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
US8206360B2 (en) 2005-02-01 2012-06-26 Intelliject, Inc. Devices, systems and methods for medicament delivery
US8231573B2 (en) 2005-02-01 2012-07-31 Intelliject, Inc. Medicament delivery device having an electronic circuit system
US7731686B2 (en) 2005-02-01 2010-06-08 Intelliject, Inc. Devices, systems and methods for medicament delivery
CA2594627C (en) * 2005-02-01 2012-04-17 Intelliject, Llc Devices, systems, and methods for medicament delivery
US8361026B2 (en) 2005-02-01 2013-01-29 Intelliject, Inc. Apparatus and methods for self-administration of vaccines and other medicaments
US9022980B2 (en) * 2005-02-01 2015-05-05 Kaleo, Inc. Medical injector simulation device
US8226610B2 (en) * 2005-02-01 2012-07-24 Intelliject, Inc. Medical injector with compliance tracking and monitoring
EP2332408B1 (de) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Behandlung neurologischer Störungen
WO2006089232A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against cd30 lacking fucosyl residues
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
WO2006100111A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
CN119119271A (zh) 2005-03-23 2024-12-13 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP2674165B1 (de) 2005-03-31 2016-10-12 The General Hospital Corporation Agonisten für den rezeptor des hepatozyten-wachstumsfaktors zur stimulierung von lymphangiogenese
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
KR20080025373A (ko) 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 1-데옥시노지리마이신 및 유도체를 이용한 폼페병의 치료방법
HUE030701T2 (hu) 2005-05-27 2017-05-29 Biogen Ma Inc Tweak-kötõ antitestek
US20060271014A1 (en) * 2005-05-31 2006-11-30 Mallinckrodt Inc. Heat retention device for a syringe and methods of use
US20070118093A1 (en) * 2005-06-20 2007-05-24 Von Muhlen Marcio G High-speed jet devices for drug delivery
HRP20080053A2 (hr) 2005-07-01 2009-08-31 Medarex Ljudska monoklonska protutijela na ligand 1 za programiranu smrt stanice (pd-l1)
US20100119525A1 (en) * 2005-08-01 2010-05-13 Mount Sinai Schoool Of Medicine Of New York University Method for extending longevity using npc1l1 antagonists
CA2616859C (en) * 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
US8591457B2 (en) * 2005-08-10 2013-11-26 Alza Corporation Method for making a needle-free jet injection drug delivery device
EP1762575A1 (de) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
ES2527961T3 (es) 2005-09-26 2015-02-02 Medarex, L.L.C. Anticuerpos monoclonales humanos para CD70
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
EP1948271B1 (de) 2005-11-17 2013-10-02 Zogenix, Inc. Abgabe von viskosen formulierungen durch nadellose injektion
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
JP2009518080A (ja) * 2005-12-05 2009-05-07 中山博泰薬械有限公司 自動注射器
SG174783A1 (en) 2005-12-08 2011-10-28 Medarex Inc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
KR101441368B1 (ko) 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
PT1986612E (pt) 2006-02-07 2012-11-06 Shire Human Genetic Therapies Composição estável de glucocerebrosidase
AU2007215305B2 (en) * 2006-02-09 2013-09-12 Deka Products Limited Partnership Pumping fluid delivery systems and methods using force application assembly
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US20080279877A1 (en) * 2006-02-13 2008-11-13 Fraunhofer U.S.A. Inc. HPV antigens, vaccine compositions, and related methods
KR20080106433A (ko) * 2006-02-13 2008-12-05 프라운호퍼 유에스에이, 인코포레이티드 인플루엔자 항원, 백신 조성물 및 관련 방법
SG169997A1 (en) * 2006-02-17 2011-04-29 Alan L Buchman Catheter cleaning devices
WO2007106415A2 (en) * 2006-03-10 2007-09-20 Massachusetts Institute Of Technology Triggered self-assembly conjugates and nanosystems
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US20080045471A1 (en) * 2006-03-27 2008-02-21 North Don A Nucleic Acids For Apoptosis Of Cancer Cells
EP1998802A2 (de) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US20080003220A1 (en) * 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
CA2652815C (en) 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
CA2656298A1 (en) * 2006-06-02 2007-12-13 President And Fellows Of Harvard College Protein surface remodeling
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CA2655997A1 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
WO2008003319A1 (en) 2006-07-04 2008-01-10 Genmab A/S Cd20 binding molecules for the treatment of copd
US20080033347A1 (en) * 2006-08-03 2008-02-07 Becton, Dickinson And Company Detachable needle syringe having reduced dead space
US7618396B2 (en) * 2006-08-09 2009-11-17 Avant Medical Corp. Injection system with hidden needles
WO2008021367A2 (en) * 2006-08-11 2008-02-21 President And Fellows Of Harvard College Moenomycin biosynthesis-related compositions and methods of use thereof
EP2046834B9 (de) 2006-08-11 2013-04-10 Ono Pharmaceutical Co., Ltd. Monoklonale antikörper gegen stromal derived factor-1 (sdf-1-)
US20090269342A1 (en) * 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20080241918A1 (en) * 2006-08-14 2008-10-02 Ram Sasisekharan Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2008030611A2 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US20090263422A1 (en) 2006-09-15 2009-10-22 Emmanuel Jules Hanon Influenza vaccine
US7942845B2 (en) * 2006-09-19 2011-05-17 Bioject, Inc. Needle-free injector and process for providing serial injections
ES2553553T3 (es) 2006-10-02 2015-12-10 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
MX2009003635A (es) * 2006-10-06 2009-04-22 Amgen Inc Formulaciones de anticuerpos estables.
US7547293B2 (en) * 2006-10-06 2009-06-16 Bioject, Inc. Triggering mechanism for needle-free injector
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
MX2009003325A (es) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
DK2068922T3 (da) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
CA2666492C (en) * 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
US20090124996A1 (en) * 2006-11-03 2009-05-14 Scott Heneveld Apparatus and methods for injecting high viscosity dermal fillers
JP2010509920A (ja) 2006-11-15 2010-04-02 メダレックス インコーポレーティッド Ｂｔｌａに対するヒトモノクローナル抗体および使用方法
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
MX2009005727A (es) 2006-12-01 2009-08-27 Anterios Inc Nanoparticulas de entidad anfifilica.
CA2671850A1 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
US8491868B2 (en) 2006-12-26 2013-07-23 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
WO2008083209A2 (en) * 2006-12-29 2008-07-10 Amir Genosar Hypodermic drug delivery reservoir and apparatus
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
WO2008098165A2 (en) * 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
WO2008103997A2 (en) * 2007-02-23 2008-08-28 Bioject Inc. Needle-free injection devices and drug delivery systems therefor
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
EP2144600A4 (de) 2007-04-04 2011-03-16 Massachusetts Inst Technology Poly (aminsäure)-zielmoleküle
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
CA2685558A1 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
CA2684699C (en) * 2007-06-14 2017-03-21 Berna Biotech Ag Intradermal influenza vaccine
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
JP5476295B2 (ja) 2007-06-26 2014-04-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
WO2009009759A2 (en) * 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
DE102007034871A1 (de) * 2007-07-24 2009-01-29 Lts Lohmann Therapie-Systeme Ag Einweginjektor mit handbetätigbarem Kolben
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
WO2009026397A2 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2190469B1 (de) 2007-09-04 2015-02-25 Compugen Ltd. Polypeptide und polynukleotide und ihre verwendung als zielmolekül zur herstellung von arzneimitteln und biologika
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
US8604004B2 (en) * 2007-10-04 2013-12-10 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
ES2627233T3 (es) * 2007-10-12 2017-07-27 Massachusetts Institute Of Technology Nanotecnología de vacunas
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009049350A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
CA2700433A1 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
US20090137949A1 (en) * 2007-11-26 2009-05-28 Bioject Inc. Needle-free injection device with nozzle auto-disable
US8617099B2 (en) * 2007-11-26 2013-12-31 Bioject Inc. Injection device plunger auto-disable
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
WO2009086250A1 (en) 2007-12-21 2009-07-09 Aesthetic Sciences Corporation Self-contained pressurized injection device
RU2010131797A (ru) 2007-12-28 2012-02-10 Эктивпак, Инк. (Us) Дозатор и упаковка лекарственного средства, пригодные для введения лекарственного вещества в объект лечения
DE102008011873A1 (de) 2007-12-30 2009-07-09 Idelevich, Evgeny Applikationsvorrichtung und -verfahren zur automatisierten Medikamentenabgabe bei arteriellem Hypertonus
CN101951927A (zh) * 2008-01-03 2011-01-19 麻省理工学院 诱饵流感疗法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965398B (zh) 2008-01-22 2015-03-18 圣保罗州研究奖励基金会 肽、组合物及其应用
MY150246A (en) 2008-02-05 2013-12-31 Bristol Myers Squibb Co Alpha 5 - beta 1 antibodies and their uses
EP2250279B1 (de) 2008-02-08 2016-04-13 MedImmune, LLC Anti-ifnar1-antikörper mit reduzierter fc-ligandenaffinität
CA2721060A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
HUE026586T2 (hu) 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
CN102066405B (zh) * 2008-04-28 2015-09-30 哈佛大学校长及研究员协会 用于细胞穿透的超荷电蛋白
JP2011518881A (ja) * 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド 片頭痛の治療のための製剤
EA201001734A1 (ru) 2008-05-02 2011-10-31 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
USD994111S1 (en) 2008-05-12 2023-08-01 Kaleo, Inc. Medicament delivery device cover
US8021344B2 (en) 2008-07-28 2011-09-20 Intelliject, Inc. Medicament delivery device configured to produce an audible output
MX2010012931A (es) * 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.
ES2677599T3 (es) 2008-05-30 2018-08-03 Allergan, Inc. Dispositivo de inyección para rellenos de aumento de tejido blando, agentes bioactivos y otros materiales biocompatibles en forma líquida o de gel
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
CN106822891A (zh) 2008-06-20 2017-06-13 诺华公司 具有降低的聚集的免疫球蛋白
CN102076333A (zh) 2008-06-26 2011-05-25 安特里奥公司 真皮递送
EP2318832B1 (de) 2008-07-15 2013-10-09 Academia Sinica Glycan-arrays auf objektträgern mit ptfe-aluminiumbeschichtung und entsprechende verfahren
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN102159203A (zh) * 2008-07-23 2011-08-17 麻省理工学院 组蛋白脱乙酰酶1(hdac1)的活化防范dna损伤和增加神经元存活
ES2752025T3 (es) 2008-07-25 2020-04-02 Wagner Richard W Métodos de cribado de proteínas
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
WO2010033882A2 (en) * 2008-09-18 2010-03-25 Becton, Dickinson And Company Medical injector with slidable sleeve activation
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
JP5823867B2 (ja) 2008-10-29 2015-11-25 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の製剤
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
PL2384210T3 (pl) 2008-12-02 2018-01-31 Allergan Inc Urządzenie do iniekcji
US9545483B2 (en) * 2008-12-02 2017-01-17 Sanofi-Aventis Deutschland Gmbh Drive assembly suitable for use in a medication delivery device and medication delivery device
EP2865689A1 (de) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F Polypeptide und Polynukleotide und Verwendungen davon als Arzneimittel-Target zur Herstellung von Arzneimitteln und Biologika
WO2010067345A1 (en) * 2008-12-08 2010-06-17 Perf-Action Technologies Ltd. Erosion prevention for o-rings in a high pressure injection device
US9637746B2 (en) 2008-12-15 2017-05-02 Greenlight Biosciences, Inc. Methods for control of flux in metabolic pathways
EP3998479A1 (de) 2008-12-19 2022-05-18 Medirista Biotechnologies AB Oxidiertes cardiolipin als neuartiger proinflammatorischer faktor
WO2010074760A1 (en) * 2008-12-22 2010-07-01 Greenlight Biosciences Compositions and methods for the production of a compound
PL2403878T3 (pl) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. W pełni ludzkie przeciwciała specyficzne dla CADM1
GB0904540D0 (en) 2009-03-17 2009-04-29 Biotica Tech Ltd Novel compounds and methods for their production
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
AU2010234449A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
CN102625661B (zh) 2009-04-09 2015-05-27 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的方法
SG175166A1 (en) * 2009-04-17 2011-11-28 Biogen Idec Inc Compositions and methods to treat acute myelogenous leukemia
PE20121397A1 (es) 2009-04-20 2012-10-23 Oxford Biotherapeutics Ltd Anticuerpos especificos para cadherina-17
EP2243505B1 (de) * 2009-04-23 2018-02-14 Bayer Healthcare LLC Spritzenbaugruppen, Verfahren zum Bilden von Spritzenbaugruppen
KR101836501B1 (ko) 2009-04-27 2018-03-08 노파르티스 아게 근육 성장을 증가시키기 위한 조성물 및 방법
US8715657B2 (en) 2009-04-27 2014-05-06 Novartis Ag Therapeutic antibodies binding IL12Rβ1
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
EP2448970B1 (de) 2009-05-04 2014-07-09 Abbott Research B.V. Antikörper gegen den nervenwachstumsfaktor (ngf) mit verbesserter in-vivo-stabilität
AU2010249046A1 (en) 2009-05-13 2011-12-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
US9149465B2 (en) * 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) * 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) * 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
EP2438046A4 (de) 2009-06-01 2013-04-17 Harvard College O-glcnac-transferasehemmer und verwendungen davon
US8974423B2 (en) * 2009-06-01 2015-03-10 Sanofi-Aventis Deutschland Gmbh Resettable drug delivery device
CA2769999C (en) 2009-06-01 2020-02-18 Shriners Hospitals For Children A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof
RU2569186C2 (ru) 2009-06-04 2015-11-20 Новартис Аг СПОСОБЫ ИДЕНТИФИКАЦИИ САЙТОВ ДЛЯ КОНЪЮГАЦИИ IgG
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
AR077594A1 (es) 2009-07-31 2011-09-07 Organon Nv Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0914589D0 (en) 2009-08-20 2009-09-30 Biotica Tech Ltd Novel compounds and methods for their production
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
GB0917817D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
GB0917816D0 (en) 2009-10-12 2009-11-25 Biotica Tech Ltd Novel compounds and methods for their production
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
CA2777242A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
PL2490532T3 (pl) 2009-10-19 2017-05-31 Amicus Therapeutics, Inc. Nowe kompozycje do zapobiegania i/lub leczenia zaburzeń zwyrodnieniowych ośrodkowego układu nerwowego
RU2608520C2 (ru) 2009-10-19 2017-01-19 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения лизосомных болезней накопления
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
JP2013509869A (ja) 2009-11-05 2013-03-21 ノバルティス アーゲー 線維症の進行の予測用バイオマーカー
EP2507265B1 (de) 2009-12-01 2016-05-11 Compugen Ltd. Heparanase Spice-Variante T5 spezifischer Antikörper und dessen Verwendung.
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US20110137260A1 (en) 2009-12-07 2011-06-09 Allergan, Inc. Slotted syringe
JP5819848B2 (ja) 2009-12-18 2015-11-24 アローヘッド リサーチ コーポレイション Ｈｓｆ１関連疾患を処置するための有機組成物
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
JP6210685B2 (ja) 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
WO2011097233A1 (en) * 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
EP2544674B1 (de) 2010-03-08 2017-10-25 Sloan Kettering Institute For Cancer Research Cdc7 kinase hemmer und deren verwendung
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN102892430A (zh) 2010-03-17 2013-01-23 雅培研究有限公司 抗神经生长因子（ngf）抗体组合物
WO2011119549A1 (en) 2010-03-22 2011-09-29 President And Fellows Of Harvard College Trioxacarcins and uses thereof
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
SG184310A1 (en) 2010-04-13 2012-10-30 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
BR112012027080A2 (pt) 2010-04-23 2015-09-22 Novartis Ag composições orgânicas para tratar doenças relacionadas a beta - ena
SG185366A1 (en) 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8956833B2 (en) 2010-05-07 2015-02-17 Greenlight Biosciences, Inc. Methods for control of flux in metabolic pathways through enzyme relocation
MX367382B (es) 2010-05-11 2019-08-19 Lantheus Medical Imaging Inc Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores.
EP2571550B1 (de) 2010-05-19 2014-05-14 Allergan, Inc. Modulare injektionsvorrichtung
JP5857043B2 (ja) 2010-06-18 2016-02-10 大鵬薬品工業株式会社 Ｐｒｐｋ−ｔｐｒｋｂモジュレーター及びその使用
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
US9072713B2 (en) 2010-07-01 2015-07-07 The Texas A&M University System Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function
CN108314733A (zh) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012021874A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with thioether linkers
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
KR101988063B1 (ko) 2010-08-31 2019-09-30 그린라이트 바이오사이언시스, 아이엔씨. 프로테아제 조작을 통한 대사 경로에서 유동의 제어 방법
CN104958813A (zh) 2010-09-15 2015-10-07 周吉尼克斯股份有限公司 无针注射器和优化注射性能的无针注射器设计参数
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
CA2811023A1 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
CA2812057A1 (en) 2010-09-28 2012-04-05 Kahr Medical Ltd. Compositions and methods for treatment of hematological malignancies
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
CA2813304A1 (en) 2010-10-01 2012-04-05 Biogen Idec Ma Inc. Interferon-beta for use as monotherapy or in combination with other cancer therapies
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
EP2624864B1 (de) 2010-10-04 2017-12-06 Massachusetts Institute of Technology Hämagglutinin-polypeptide und -reagenzien sowie verfahren in zusammenhang damit
EP2625203A1 (de) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1-antikörper und ihre verwendung zur behanldung von autoimmun- und entzündungserkrankungen
CN103269729A (zh) 2010-11-03 2013-08-28 尤尔科医疗有限公司 便携式真空装置
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
SG190321A1 (en) 2010-11-24 2013-06-28 Novartis Int Pharm Ltd Fusion enzymes having n-acetylglucosaminyltransferase activity
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
CN103747782A (zh) 2011-01-24 2014-04-23 安特里奥公司 纳米颗粒组合物
EP2667945A1 (de) 2011-01-24 2013-12-04 Anterios, Inc. Ölzusammensetzungen
KR20140005998A (ko) 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US9173999B2 (en) 2011-01-26 2015-11-03 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CN103889219A (zh) 2011-03-03 2014-06-25 特萨斯制药有限责任公司 包含C16:1n7-棕榈油酸酯的组合物和方法
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20130281932A1 (en) * 2011-03-30 2013-10-24 Ziv Harish Palm-based injector actuation and safety surfaces
EP2691396B1 (de) 2011-03-30 2016-08-10 Brown University Enopeptine, verwendungen davon und syntheseverfahren dafür
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
CA2833850A1 (en) * 2011-04-19 2012-10-26 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
UY34073A (es) 2011-05-17 2013-01-03 Glaxosmithkline Biolog Sa Vacuna mejorada de streptococcus pneumoniae y métodos de preparación.
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
US20140193408A1 (en) 2011-06-16 2014-07-10 Novartis Ag Soluble proteins for use as therapeutics
CN103608030A (zh) 2011-06-21 2014-02-26 昂科发克特公司 用于治疗和诊断癌症的组合物和方法
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
EP2726508B1 (de) 2011-06-28 2017-08-09 Oxford BioTherapeutics Ltd Antikörper gegen adp-ribosyl- cyclase-2
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
PT2726099T (pt) 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
EP2734530A1 (de) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclische verbindungen und ihre verwendung
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
EP2734510B8 (de) 2011-07-22 2019-05-29 Massachusetts Institute of Technology Aktivatoren der klasse i histon-deacetlyasen (hdacs) und verwendungen davon
EP2736928B1 (de) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Gegen erbb3-gerichtete sur-bindende proteine
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2013030778A2 (en) 2011-09-02 2013-03-07 Novartis Ag Organic compositions to treat hsf1-related diseases
KR20190015765A (ko) 2011-09-09 2019-02-14 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
EP2753702B1 (de) 2011-09-09 2021-12-15 GreenLight Biosciences, Inc. Zellfreie herstellung von carbapenemen
WO2013039861A2 (en) 2011-09-12 2013-03-21 modeRNA Therapeutics Engineered nucleic acids and methods of use thereof
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CN104136461B (zh) 2011-09-22 2021-06-08 安姆根有限公司 Cd27l抗原结合蛋白
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
RU2474437C1 (ru) * 2011-10-13 2013-02-10 Борис Владимирович Смоляров Способ осуществления безыгольной инъекции
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CA2855155A1 (en) 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US8603028B2 (en) 2011-11-18 2013-12-10 Allergan, Inc. Injection device having an angled tip portion
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2793940B1 (de) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogatbindungsproteine
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
WO2013102674A2 (en) 2012-01-05 2013-07-11 Novartis International Pharmaceutical Ltd. Protease deficient filamentous fungal cells and methods of use thereof
JP6158833B2 (ja) 2012-01-09 2017-07-05 アローヘッド ファーマシューティカルズ インコーポレイテッド ベータ−カテニン関連疾患を処置するための有機組成物
US10130800B2 (en) 2012-01-27 2018-11-20 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
SG2014008304A (en) 2012-02-01 2014-06-27 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
ES2615268T3 (es) 2012-02-13 2017-06-06 Bristol-Myers Squibb Company Compuestos de enediino, conjugados de los mismos y usos y métodos para ello
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG10201606775YA (en) 2012-02-15 2016-10-28 Aileron Therapeutics Inc Peptidomimetic macrocycles
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
MX354127B (es) 2012-03-27 2018-02-14 Amicus Therapeutics Inc Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central.
EP2830659A1 (de) 2012-03-27 2015-02-04 Novartis AG Behandlung von fibrose
US9902985B2 (en) 2012-04-06 2018-02-27 President And Fellows Of Harvard College Chemoenzymatic methods for synthesizing moenomycin analogs
US9273084B2 (en) 2012-04-06 2016-03-01 President And Fellows Of Harvard College Moenomycin analogs, methods of synthesis, and uses thereof
WO2013151697A1 (en) 2012-04-06 2013-10-10 President And Fellows Of Harvard College Methods and compounds for identifying glycosyltransferase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
EP2841098A4 (de) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanopartikel zur behandlung von allergien
US20130304017A1 (en) * 2012-05-09 2013-11-14 Bioject, Inc. Peformance of needle-free injection according to known relationships
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP2846833A4 (de) 2012-05-10 2016-01-06 Massachusetts Inst Technology Mittel zur influenzaneutralisierung
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9399672B2 (en) 2012-05-17 2016-07-26 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Hepatitis C virus neutralizing antibody
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
US9522235B2 (en) 2012-05-22 2016-12-20 Kaleo, Inc. Devices and methods for delivering medicaments from a multi-chamber container
US9695454B2 (en) 2012-05-23 2017-07-04 Glykos Finland Oy Production of fucosylated glycoproteins
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
HK1203358A1 (en) 2012-06-05 2015-10-30 The Australian National University Vaccination with interleukin-4 antagonists
GB201210082D0 (en) * 2012-06-07 2012-07-25 Consort Medical Plc Improved syringe
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
FI3421486T3 (fi) 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
USD695892S1 (en) 2012-07-23 2013-12-17 Pharmajet, Inc. Needle-free syringe
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
US10309430B2 (en) * 2012-08-10 2019-06-04 Confluent Surgical, Inc. Pneumatic actuation assembly
WO2014028463A1 (en) 2012-08-14 2014-02-20 Allergan, Inc. Syringe for mixing and dispensing adipose tissue
JP6302909B2 (ja) 2012-08-18 2018-03-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ シアリダーゼの同定および画像化のための細胞透過性プローブ
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
WO2014052647A2 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
ES2719776T3 (es) 2012-10-12 2019-07-16 Broad Inst Inc Inhibidores de GSK3 y métodos de uso de los mismos
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US20140114248A1 (en) 2012-10-24 2014-04-24 Nuance Designs, LLC Power pack for an autoinjector
WO2014065822A1 (en) 2012-10-26 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hepatitis c virus neutralizing epitopes, antibodies, and methods
EP2914296B2 (de) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Behandlung von krebs mit pi3-kinase-isoformmodulatoren
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
US9567301B2 (en) 2012-11-02 2017-02-14 Dana-Farber Cancer Institute, Inc. Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors
AU2013344815B2 (en) * 2012-11-13 2018-07-26 Construct Medical Pty Ltd A portable suction device
KR101651448B1 (ko) 2012-11-21 2016-08-26 토포카인 쎄라퓨틱스, 인코포레이티드 체지방을 국소적으로 증가시키는 방법 및 조성물
US9775915B2 (en) 2012-11-26 2017-10-03 President And Fellows Of Harvard College Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
EA034757B1 (ru) 2012-12-10 2020-03-17 Байоджен Ма Инк. Антитела против антигена 2 дендритных клеток крови и их применение
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe
EP3626735A1 (de) 2012-12-18 2020-03-25 Novartis AG Stabilisierte insulinähnliche wachstumsfaktorpolypeptide
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102024417B1 (ko) 2012-12-21 2019-11-07 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
AU2013370241B2 (en) 2012-12-27 2018-02-15 Kaleo, Inc. Devices, systems and methods for locating and interacting with medicament delivery systems
EP3434774A1 (de) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
CA2898633C (en) 2013-02-07 2021-07-13 Massachusetts Institute Of Technology Human adaptation of h5 influenza
EP3656786B1 (de) 2013-02-08 2024-08-28 Novartis AG Anti-il-17a-antikörper und deren verwendung zur behandlung von autoimmun- und entzündungserkrankungen
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
EP2962100B1 (de) 2013-02-28 2021-07-28 Caprion Proteomics Inc. Tuberkulose biomarker und deren verwendung
EP2968391A1 (de) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Langlebige polynukleotidmoleküle
CN110105434B (zh) 2013-03-13 2024-09-17 哈佛大学的校长及成员们 钉合且缝合的多肽及其用途
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
SG11201504260UA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing and using the same
SG11201507365VA (en) 2013-03-14 2015-10-29 Abbvie Inc Low acidic species compositions and methods for producing the same using displacement chromatography
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US20160017041A1 (en) 2013-03-15 2016-01-21 Biogen Ma Inc. Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20160122436A1 (en) 2013-03-15 2016-05-05 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
EP2970194A1 (de) 2013-03-15 2016-01-20 Infinity Pharmaceuticals, Inc. Salze und feste formen von isochinolinonen und zusammensetzung damit sowie verfahren zur verwendung davon
MX375502B (es) 2013-04-03 2025-03-04 N Fold Llc Composiciones de nanoparticulas novedosas.
EP4095146A1 (de) 2013-04-04 2022-11-30 President And Fellows Of Harvard College Makrolide sowie verfahren zu deren herstellung und verwendung
EP2983659B1 (de) 2013-04-09 2019-11-20 Massachusetts Institute of Technology Wirkstofffreisetzendes polymer und verwendungen davon
WO2014179464A1 (en) 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Human adaptation of h3 influenza
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
NO2753788T3 (de) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
AU2014273946B2 (en) 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
CN105555803B (zh) 2013-05-30 2019-09-10 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
AU2014278231B2 (en) 2013-06-11 2017-05-25 KALA BIO, Inc. Urea derivatives and uses thereof
JP2016523241A (ja) 2013-06-14 2016-08-08 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化されたポリペプチドインスリン受容体調節剤
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
WO2014207067A1 (en) 2013-06-26 2014-12-31 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) The (s)-enantiomer of mepazine
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
AU2014304545A1 (en) 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
DK3030671T3 (en) 2013-08-05 2019-01-21 Greenlight Biosciences Inc MODIFIED PROTEINS WITH A PROTEASE CLEANING PLACE
TWI532511B (zh) * 2013-08-16 2016-05-11 京華堂實業股份有限公司 無針型注射系統及其注射方法
CN105682666B (zh) 2013-09-06 2021-06-01 中央研究院 使用醣脂激活人类iNKT细胞
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
KR20160091888A (ko) 2013-10-02 2016-08-03 노파르티스 아게 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051234A2 (en) 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160561A1 (es) 2013-10-11 2016-06-03 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento de cancer
WO2015057894A1 (en) 2013-10-15 2015-04-23 Massachusetts Institute Of Technology Methods for treating polycystic kidney disease and polycystic liver disease
US9902986B2 (en) 2013-10-16 2018-02-27 Massachusetts Institute Of Technology Enterobactin conjugates and uses thereof
CA2927920A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015057939A1 (en) 2013-10-18 2015-04-23 Biogen Idec Ma Inc. Anti-s1p4 antibodies and uses thereof
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3062618B1 (de) 2013-11-01 2020-02-05 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
AU2014368449C1 (en) 2013-12-20 2021-05-06 Intervet International B.V. Canine antibodies with modified CH2-CH3 sequences
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
KR20160101162A (ko) 2013-12-24 2016-08-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 코르티스타틴 유사체 및 그의 합성 및 용도
KR102534681B1 (ko) 2013-12-24 2023-05-18 잔센파마슈티카엔.브이. 항-vista 항체 및 단편
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
TW201613861A (en) 2014-02-12 2016-04-16 Amicus Therapeutics Inc Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC
CA2941357A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
WO2015143012A1 (en) 2014-03-19 2015-09-24 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
CN120514834A (zh) 2014-03-28 2025-08-22 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10039816B2 (en) 2014-04-30 2018-08-07 Massachusetts Institute Of Technology Siderophore-based immunization against gram-negative bacteria
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
KR20170005142A (ko) 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
TWI732738B (zh) 2014-05-28 2021-07-11 中央研究院 抗TNF-α醣抗體及其用途
JP6612017B2 (ja) * 2014-06-03 2019-11-27 株式会社ダイセル 無針注射器による注射システム
KR102204937B1 (ko) 2014-06-06 2021-01-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
PT3157916T (pt) 2014-06-19 2019-03-25 Ariad Pharma Inc Compostos heteroarilo para inibição de cinase
EP2959931A1 (de) 2014-06-24 2015-12-30 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
EP3164379A1 (de) 2014-07-02 2017-05-10 Massachusetts Institute of Technology Lipidoide aus polyaminfettsäure und verwendungen davon
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
EP3169699A4 (de) 2014-07-18 2018-06-20 The University of Washington Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AR101400A1 (es) 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
EP2979714A1 (de) 2014-08-02 2016-02-03 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend eine Membran
CA2958018A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
WO2016025643A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Brush-poly(glycoamidoamine)-lipids and uses thereof
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MY184288A (en) 2014-08-19 2021-03-30 Merck Sharp & Dohme Llc Anti-tigit antibodies
EP3185885B1 (de) 2014-08-26 2020-08-19 Compugen Ltd. Polypeptide und verwendungen davon als arzneimittel zur behandlung von autoimmunerkrankungen
EP3191500A4 (de) 2014-09-08 2018-04-11 Academia Sinica Aktivierung menschlicher inkt-zellen mithilfe von glykolipiden
EP2993174A1 (de) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridinderivate und deren Verwendung in der Therapie
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2017531642A (ja) 2014-10-03 2017-10-26 マサチューセッツ インスティテュート オブ テクノロジー エボラ糖タンパク質に結合する抗体およびその使用
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
EP3760618A1 (de) 2014-10-21 2021-01-06 ARIAD Pharmaceuticals, Inc. Kristalline formen von 5-chlor-n4-[-2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2,4-diamin
EP3011988A1 (de) 2014-10-22 2016-04-27 LTS LOHMANN Therapie-Systeme AG Nadellose Injektionsvorrichtung aufweisend ein Gel und eine Membran
US20180015101A1 (en) 2014-10-28 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for antigen-specific tolerance
EP3217982B1 (de) 2014-11-10 2025-05-28 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazinderivate als inhibitoren von nichtapoptotischem reguliertem zelltod
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3461904A1 (de) 2014-11-10 2019-04-03 ModernaTX, Inc. Alternative nukleinsäuremoleküle mit reduziertem uracilgehalt und verwendungen davon
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
KR20230125855A (ko) 2014-11-21 2023-08-29 브리스톨-마이어스 스큅 컴퍼니 Cd73에 대항한 항체 및 그의 용도
US10253045B2 (en) 2014-11-26 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof
EP3227341A1 (de) 2014-12-02 2017-10-11 CeMM - Forschungszentrum für Molekulare Medizin GmbH Anti-mutante calreticulin-antikörper und deren verwendung bei der diagnose und therapie von myeloiden malignomen
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
CA2969467A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
EP3233912B1 (de) 2014-12-19 2021-05-19 Regenesance B.V. Antikörper zur bindung von humanem c6 und verwendungen davon
CN107206256A (zh) 2014-12-23 2017-09-26 索隆-基特林癌症研究协会 榴菌素b的多形体
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
JP6863897B2 (ja) 2015-01-09 2021-04-21 アダルタ・リミテッド Ｃｘｃｒ４結合分子
AU2016206808A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016145230A1 (en) 2015-03-10 2016-09-15 Unger Jacob G Multiple needle injector
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
JP2018511655A (ja) 2015-03-20 2018-04-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2980004C (en) 2015-03-24 2023-10-10 Kaleo, Inc. Devices and methods for delivering a lyophilized medicament
EP3273966B1 (de) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
MY193444A (en) 2015-03-30 2022-10-13 Greenlight Biosciences Inc Cell-free production of ribonucleic acid
HK1250514A1 (zh) 2015-04-02 2018-12-21 Intervet International B.V. 针对犬白介素-4受体α的抗体
JP2018510913A (ja) 2015-04-10 2018-04-19 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 抗ウイルス剤としての使用のためのピロン誘導体
CR20170510A (es) 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
PT3283524T (pt) 2015-04-17 2023-06-05 Amgen Res Munich Gmbh Construções de anticorpos biespecíficos para cdh3 e cd3
CA2984250A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
BR112017023158A2 (pt) 2015-04-30 2018-07-24 Harvard College anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos
WO2016178591A2 (en) 2015-05-05 2016-11-10 Gene Predit, Sa Genetic markers and treatment of male obesity
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
WO2016188932A2 (en) 2015-05-22 2016-12-01 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Combination compositions and their use in methods for treating obesity and obesity-related disorders
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
US11078259B2 (en) * 2015-06-05 2021-08-03 Joslin Diabetes Center, Inc. Methods and compositions for promoting thermogenic potential
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN107847668A (zh) * 2015-06-15 2018-03-27 纽昂斯设计康涅狄格有限责任公司 带有气流调节器的气体促动式自动注射器
JP2017000667A (ja) 2015-06-16 2017-01-05 国立大学法人三重大学 無針注射器及びそれを用いた注射対象領域へのｄｎａ導入方法
US10201618B2 (en) 2015-06-19 2019-02-12 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CA2990950C (en) 2015-06-30 2025-06-10 Kaleo, Inc. AUTO-INJECTORS INTENDED FOR ADMINISTRATING MEDICATION INSIDE A PRE-FILLED SYRINGE
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
DK3322733T3 (da) 2015-07-13 2021-10-18 Compugen Ltd Hide1-sammensætninger og fremgangsmåder
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
AU2016324310B2 (en) 2015-09-17 2021-04-08 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP4101930A1 (de) 2015-09-17 2022-12-14 ModernaTX, Inc. Polynukleotide mit stabilisierendem schwanzbereich
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
JP6940853B2 (ja) 2015-09-30 2021-09-29 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン４受容体経路関連障害を治療する方法
WO2017059389A1 (en) 2015-10-01 2017-04-06 Kythera Biopharmaceuticals, Inc. Compositions comprising a statin for use in methods of adipolysis
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3371217B1 (de) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Screening verfahren für multispezifische antikörper
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
KR102630475B1 (ko) 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 항 인간 ip-10 항체 및 이의 용도
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US10596248B2 (en) 2015-12-09 2020-03-24 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
DK3390451T3 (da) 2015-12-18 2025-03-17 Intervet Int Bv Kaniniserede humane antistoffer mod il-4r-alpha hos mennesker og hunde
SI3394030T1 (sl) 2015-12-22 2022-04-29 Modernatx, Inc. Sestave za doziranje sredstev v celice
JOP20170013B1 (ar) 2016-01-22 2021-08-17 Merck Sharp & Dohme أجسام xi مضادة لعامل مضاد للتجلط
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
TWI767899B (zh) 2016-02-03 2022-06-21 德商安美基研究（慕尼黑）公司 Psma及cd3雙特異性t細胞嚙合抗體構築體
CN109219617A (zh) 2016-02-03 2019-01-15 安进研发（慕尼黑）股份有限公司 Bcma和cd3双特异性t细胞接合抗体构建体
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
RU2018131123A (ru) 2016-02-17 2020-03-17 Новартис Аг Антитела к tgf-бета2
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
IL261602B2 (en) 2016-03-04 2024-06-01 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
EA038691B1 (ru) 2016-03-28 2021-10-05 Айкор Медикэл Системс, Инк. Устройство для доставки терапевтических средств
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
CR20180525A (es) 2016-04-06 2019-02-14 Greenlight Biosciences Inc Producción de ácido ribonucleico libre de células
WO2017176476A1 (en) 2016-04-08 2017-10-12 Allergan, Inc. Aspiration and injection device
EP3442579A4 (de) 2016-04-15 2019-12-18 Immunext Inc. Anti-human-vista-antikörper und verwendung davon
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US11230591B2 (en) 2016-04-20 2022-01-25 Merck Sharp & Dohme Corp. CMV neutralizing antigen binding proteins
PT3445850T (pt) 2016-04-22 2021-12-06 BioNTech SE Métodos para proporcionar arn de cadeia simples
EP3932453B1 (de) * 2016-04-29 2025-11-05 Altaviz LLC Selbständig energieversorgte spritze
NZ775714A (en) 2016-05-04 2024-12-20 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
EP3455256A1 (de) 2016-05-09 2019-03-20 Bristol-Myers Squibb Company Tl1a-antikörper und verwendungen davon
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
MX2018014887A (es) 2016-06-03 2019-06-06 Sanofi Pasteur Inc Modificación de polipéptidos de hemaglutinina de influenza transformados por ingeniería genética.
US10105449B2 (en) 2016-06-07 2018-10-23 Massachusetts Institute Of Technology Drug delivery polymers and uses thereof
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN116425879A (zh) 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
EP3468537A1 (de) 2016-06-14 2019-04-17 Modernatx, Inc. Stabilisierte formulierungen von lipidnanopartikeln
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10328205B2 (en) * 2016-07-07 2019-06-25 Shl Medical Ag Drug delivery device with pneumatic power pack
EP4512829A3 (de) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antikörper gegen tim3 und verwendungen davon
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor
US20180028755A1 (en) * 2016-07-28 2018-02-01 Portal Instruments, Inc. Connected health platform including needle-free injector system
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Ｓｋ生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
ES2902179T3 (es) 2016-08-19 2022-03-25 Bristol Myers Squibb Co Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso
EP3500594A4 (de) 2016-08-22 2020-03-11 Cho Pharma Inc. Antikörper, bindungsfragmente und verfahren zur verwendung
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3305781A1 (de) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemische substanzen welche die enzymatische aktivität der humanen kallikrein-related peptidase 6 (klk6) hemmen.
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
ES2908239T3 (es) 2016-10-28 2022-04-28 Astute Medical Inc Uso de anticuerpos contra timp-2 para la mejora de la función renal
EP3535280B1 (de) 2016-11-07 2022-03-16 Bristol-Myers Squibb Company Immunomodulatoren
WO2018089540A1 (en) 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
WO2018089829A1 (en) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
EP3538153B1 (de) 2016-11-11 2024-10-09 The Regents of the University of California Anti-cd46-antikörper und verfahren zur verwendung
US10857150B2 (en) 2016-11-18 2020-12-08 Abliva Ab Use of sanglifehrin macrocyclic analogues as anticancer compounds
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
ES2862922T7 (en) 2016-12-21 2025-02-26 Mereo Biopharma 3 Ltd Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3558420B1 (de) 2016-12-23 2024-09-18 Kaleo, Inc. Medikamentenabgabevorrichtung und verfahren zur abgabe von arzneimitteln an säuglinge und kinder
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
PL3562486T3 (pl) 2016-12-31 2024-09-16 Bioxcel Therapeutics, Inc. Zastosowanie podjęzykowo deksmedetomidyny w leczeniu pobudzenia
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
EP3565828B8 (de) 2017-01-05 2022-07-27 KAHR Medical Ltd. SIRPALPHA-4-1BBL FUSIONSPROTEIN UND VERFAHREN ZUR VERWENDUNG
DAVON
WO2018129451A2 (en) 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
CA3046354A1 (en) 2017-01-17 2018-07-26 Kaleo, Inc. Medicament delivery devices with wireless connectivity and event detection
WO2018133873A1 (zh) 2017-01-23 2018-07-26 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB2559553B (en) * 2017-02-06 2021-10-13 Consort Medical Plc A medicament delivery device
GB201702144D0 (en) 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
WO2018148508A1 (en) 2017-02-10 2018-08-16 Mount Tam Biotechnologies, Inc. Rapamycin analog
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170306A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3601326A4 (de) 2017-03-20 2020-12-16 The Broad Institute, Inc. Verbindungen und verfahren zur regulierung der insulinsekretion
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
BR112019020810A2 (pt) 2017-04-05 2020-04-28 The Broad Institute, Inc. compostos tricíclicos como inibidores de glicogênio sintase cinase 3 (gsk3) e usos dos mesmos
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
TW202430219A (zh) 2017-04-13 2024-08-01 荷蘭商賽羅帕公司 抗-SIRPα 抗體
US11358926B2 (en) 2017-04-25 2022-06-14 Amicus Therapeutics, Inc. Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
CN110913904A (zh) 2017-05-05 2020-03-24 美国安进公司 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
CN111405910A (zh) 2017-05-10 2020-07-10 阿尔巴朱纳治疗有限公司 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物
CN111094335B (zh) 2017-05-15 2022-08-23 罗切斯特大学 广泛中和的抗流感单克隆抗体及其用途
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
US12077501B2 (en) 2017-06-14 2024-09-03 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
KR102735038B1 (ko) 2017-06-23 2024-11-28 브리스톨-마이어스 스큅 컴퍼니 Pd-1의 길항제로서 작용하는 면역조정제
TWI850197B (zh) 2017-06-23 2024-08-01 美國馬里蘭大學巴爾的摩分校 免疫原性組成物
CA3068338A1 (en) 2017-06-23 2018-12-27 Suzhou Bojuhua Biomedical Technology Co. Ltd Monoclonal antibody targeting human tumor stem cells and use thereof
WO2019013789A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS
WO2019013790A1 (en) 2017-07-12 2019-01-17 Curza Global, Llc ANTIMICROBIAL COMPOUNDS AND USES THEREOF
CN111201036A (zh) 2017-08-22 2020-05-26 比奥根Ma公司 包含抗α(V)β(6)抗体的药物组合物和剂量方案
GB2584009B (en) 2017-08-28 2022-03-23 Revagenix Inc Aminoglycosides and uses thereof
JP2020531041A (ja) 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
JP7257393B2 (ja) 2017-10-03 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
EP3692061A1 (de) 2017-10-04 2020-08-12 Amgen Inc. Transthyretinimmunoglobulinfusionen
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
CR20200192A (es) 2017-10-11 2020-11-02 Greenlight Biosciences Inc Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos
WO2019075320A1 (en) 2017-10-12 2019-04-18 The Trustees Of Columbia University In The City Of New York INCARN OF SLC2A1 AS BIOLOGICAL SUBSTANCE, TREATMENTS AND ASSOCIATED METHODS
JP7035299B2 (ja) 2017-10-26 2022-03-15 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換融合タンパク質、ならびにその調製および使用
AU2018354318B2 (en) 2017-10-26 2024-07-04 Takeda Pharmaceutical Company Limited Formulations comprising glucocerebrosidase and isofagomine
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
JP7194481B2 (ja) 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
EP3717033B1 (de) 2017-12-01 2025-10-22 North Carolina State University Fibrinpartikel und verfahren zu ihrer herstellung
EP3724229A1 (de) 2017-12-11 2020-10-21 Amgen Inc. Kontinuierliches herstellungsverfahren für bispezifische antikörperprodukte
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
MX2020006385A (es) 2017-12-21 2020-12-07 Gliapharm Sa Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
CA3083347A1 (en) 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
TWI850208B (zh) * 2017-12-21 2024-08-01 台灣微脂體股份有限公司 緩釋型翠普登組成物及其經皮下或類似途徑使用之方法
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US12129297B2 (en) 2018-01-12 2024-10-29 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019152810A1 (en) 2018-02-02 2019-08-08 Bio-Techne Corporation Compounds that modulate the interaction of vista and vsig3 and methods of making and using
US11147864B2 (en) 2018-02-05 2021-10-19 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
KR101859735B1 (ko) 2018-02-07 2018-05-21 주식회사 피테크 무통 주사 장치
AU2019216759A1 (en) 2018-02-08 2020-08-06 Amgen Inc. Low pH pharmaceutical antibody formulation
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20200143391A (ko) 2018-03-15 2020-12-23 비온테크 알엔에이 파마슈티컬스 게엠베하 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
CN111886256B (zh) 2018-03-23 2025-01-10 百时美施贵宝公司 抗mica和/或micb抗体及其用途
US20220064274A1 (en) 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2019194858A1 (en) 2018-04-03 2019-10-10 Achaogen, Inc. Modular synthesis of aminoglycosides
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
FI3773713T3 (fi) 2018-04-06 2025-08-15 Regeneron Pharma Leptiinireseptorin agonistivasta-aine käytettäväksi luumassan lisäämiseen aineenvaihdunnan toimintahäiriöstä tai hypoleptinemiasta kärsivällä yksilöllä
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
CN112292185B (zh) 2018-04-17 2025-07-29 塞德斯医疗公司 抗cd27和抗pd-l1抗体及双特异性构建体
EP3781206A2 (de) 2018-04-20 2021-02-24 iOmx Therapeutics AG 5-thiazolcarboxamid-kinase-hemmer und verwendungen davon
KR102104080B1 (ko) * 2018-05-02 2020-04-23 주식회사 피테크 무통 주사기용 음파발진장치 및 이를 구비하는 무통 주사기
KR102107578B1 (ko) * 2018-05-02 2020-05-07 주식회사 피테크 무통 주사기용 약액주입 제어장치 및 이를 구비하는 무통 주사기
CA3096703A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
KR101907552B1 (ko) * 2018-05-03 2018-10-12 주식회사 피테크 무바늘 무통 주사 장치
MX2020012616A (es) 2018-05-25 2021-03-25 Primmune Therapeutics Inc Agonistas del receptor tipo toll (tlr7).
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
US11951286B2 (en) * 2018-06-12 2024-04-09 Banza Stamping Industry Corp. Automatic injection device for fluid
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
TW202017567A (zh) 2018-06-21 2020-05-16 美商優曼尼蒂治療股份有限公司 用於治療及預防神經病症之組成物及方法
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
CN112888431B (zh) 2018-06-27 2022-06-03 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
SG11202013167UA (en) 2018-07-11 2021-01-28 Kahr Medical Ltd SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
US11929160B2 (en) 2018-07-16 2024-03-12 Kaleo, Inc. Medicament delivery devices with wireless connectivity and compliance detection
MA53325A (fr) 2018-07-30 2021-06-09 Amgen Inc Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3
CA3105751A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Pharmaceutical formulations of masked antibodies
US20210284732A1 (en) 2018-07-31 2021-09-16 Amgen Research (Munich) Gmbh Dosing regimen for bcma-cd3 bispecific antibodies
IL280467B2 (en) 2018-08-03 2025-03-01 Amgen Res Munich Gmbh Antibody constructs for CLDN18.2 and CD3
WO2020029982A1 (en) 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
EP3853252A1 (de) 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2-antikörper und verwendungen davon
US12263248B2 (en) 2018-09-19 2025-04-01 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
KR102199724B1 (ko) * 2018-10-05 2021-01-07 주식회사 피테크 무바늘 무통 주사 장치
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
EP3870572A1 (de) 2018-10-23 2021-09-01 Myelopro Diagnostics and Research GmbH Verbindungen gegen mutiertes calreticulin
EP3643713B1 (de) 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclische kinasehemmer und verwendungen davon
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
US11827670B2 (en) 2018-11-09 2023-11-28 University Of Massachusetts Anti-CfaE antibodies and methods of use
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
EP3887397A1 (de) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antikörper mit modifizierten schweren konstanten regionen
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
CN113195532B (zh) 2018-12-18 2025-04-11 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12478739B2 (en) 2018-12-29 2025-11-25 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
CN113825748A (zh) 2019-01-16 2021-12-21 库扎环球有限责任公司 抗微生物化合物和方法
US12503452B2 (en) 2019-01-16 2025-12-23 Curza Global, Llc Antimicrobial compounds and methods
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
IL315399A (en) 2019-01-22 2024-11-01 Aeovian Pharmaceuticals Inc Mtorc modulators and uses thereof
MX2021008621A (es) 2019-01-22 2021-08-19 Genentech Inc Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020168466A1 (en) 2019-02-19 2020-08-27 Stemirna Therapeutics Co., Ltd. Modified nucleoside and synthetic methods thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
CN113661179A (zh) 2019-03-11 2021-11-16 比奥根Ma公司 含有抗lingo-1抗体的药物组合物
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20220195052A1 (en) 2019-04-08 2022-06-23 Biogen Ma Inc. Anti-integrin antibodies and uses thereof
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
KR20220010535A (ko) 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR20220019755A (ko) 2019-06-11 2022-02-17 리제너론 파마슈티칼스 인코포레이티드 PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법
TWI874409B (zh) 2019-06-13 2025-03-01 美商安進公司 生物製品製造中基於生物量之自動灌注控制
KR20220032065A (ko) 2019-07-08 2022-03-15 암젠 인크 다중특이성 트랜스타이레틴 면역글로불린 융합
EP3997114A1 (de) 2019-07-11 2022-05-18 KAHR Medical Ltd. Heterodimere und verfahren zur verwendung davon
JP7796005B2 (ja) 2019-07-15 2026-01-08 ブリストル－マイヤーズ スクイブ カンパニー 抗ｔｒｅｍ－１抗体およびその使用
EP3999541A1 (de) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antikörper gegen menschlichen trem-1 und ihre verwendungen
WO2021009187A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
CN119307505A (zh) 2019-07-15 2025-01-14 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
CN114375191A (zh) 2019-07-19 2022-04-19 比奥克斯塞尔医疗股份有限公司 非镇静的右美托咪定治疗方案
CA3148824A1 (en) 2019-07-31 2021-02-04 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
JP2022543773A (ja) 2019-07-31 2022-10-14 モデルナティエックス インコーポレイテッド 免疫細胞へのｒｎａ干渉剤の送達のための組成物及び方法
CA3145580A1 (en) * 2019-08-09 2021-02-18 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
PE20220706A1 (es) 2019-08-13 2022-05-04 Amgen Inc Muteinas de interleucina-2 para la expansion de celulas t reguladoras
US20220340643A1 (en) 2019-09-13 2022-10-27 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
EP4051692A1 (de) 2019-10-30 2022-09-07 Bristol-Myers Squibb Company Immunmodulatoren
ES2987783T3 (es) 2019-11-11 2024-11-18 Amgen Res Munich Gmbh Régimen de dosificación para agentes anti-BCMA
EP4058485A1 (de) 2019-11-13 2022-09-21 Amgen Inc. Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
WO2021097061A1 (en) 2019-11-13 2021-05-20 Curza Global, Llc Antimicrobial compounds and methods
EP4061818B1 (de) 2019-11-19 2023-12-06 Bristol-Myers Squibb Company Makrozyklische peptide als pd-l1 inhibitoren und immunomodulatoren zur behandlung von krebs und infektionserkrankungen
US20230257449A1 (en) 2019-12-11 2023-08-17 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
JP2023506922A (ja) 2019-12-20 2023-02-20 インターベット インターナショナル ベー． フェー． アトピー性皮膚炎を処置するための二重特異性イヌ化抗体
AU2020409583A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
CN114981309B (zh) 2020-01-03 2023-08-25 博奥信生物技术（南京）有限公司 结合bcma的抗体及其用途
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
KR20220122752A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US20230063238A1 (en) 2020-01-06 2023-03-02 Bristol-Myers Squibb Company Immunomodulators
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4093771A1 (de) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
KR20220133957A (ko) 2020-01-31 2022-10-05 모더나티엑스, 인크. 지질 나노입자의 제조 방법
AU2021228061A1 (en) 2020-02-27 2022-10-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibodies binding IL4R and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
US20230183292A1 (en) 2020-03-16 2023-06-15 Bristol-Myers Squibb Company Immunomodulators
AU2021240028A1 (en) 2020-03-19 2022-09-15 Amgen Inc. Antibodies against mucin 17 and uses thereof
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
EP4126902B1 (de) 2020-03-30 2023-12-06 Bristol-Myers Squibb Company Immunmodulatoren
EP4126934A1 (de) 2020-04-01 2023-02-08 University of Rochester Monoklonale antikörper gegen das hämagglutinin (ha) und die neuraminidase (na) von influenza-h3n2-viren
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
US11834485B2 (en) 2020-04-21 2023-12-05 Regeneron Pharmaceuticals, Inc. IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
EP3901151A1 (de) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
AU2021262482A1 (en) 2020-04-28 2023-01-05 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
MX2021015024A (es) 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
KR20230004799A (ko) 2020-04-29 2023-01-06 암젠 인크 제약 제형
EP4142789A1 (de) 2020-04-29 2023-03-08 Amgen Inc. Pharmazeutische formulierung
JP2023524464A (ja) 2020-04-30 2023-06-12 サイロパ ビー．ブイ． 抗ｃｄ１０３抗体
US20230242585A1 (en) 2020-05-08 2023-08-03 Bristol-Myers Squibb Company Immunomodulators
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN111529830B (zh) * 2020-05-22 2024-10-15 江阴市机电技术有限公司 一种启动稳定的给药装置
MX2022014902A (es) 2020-05-29 2023-01-04 Amgen Inc Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3.
US20240148889A1 (en) 2020-06-11 2024-05-09 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
FR3112939B1 (fr) 2020-07-31 2024-01-05 Univ Montpellier Produit universel de thérapie cellulaire et son utilisation
IL300528A (en) 2020-08-07 2023-04-01 Fortis Therapeutics Inc Immune conjugates targeting cd46 and methods of using them
WO2022046651A1 (en) 2020-08-24 2022-03-03 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
AU2021342567A1 (en) * 2020-09-21 2023-03-02 Boston Scientific Scimed, Inc. Fluid pressure indicators for medical devices
WO2022072797A1 (en) 2020-10-02 2022-04-07 Bristol-Myers Squibb Company Macrocyclic peptide boronate immunomodulators
KR20230084209A (ko) 2020-10-08 2023-06-12 브리스톨-마이어스 스큅 컴퍼니 이량체 밀라 면역조정제
WO2022076796A1 (en) 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2022081799A1 (en) 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
JP2023545182A (ja) 2020-10-15 2023-10-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファに対するイヌ化ラット抗体
WO2022092294A1 (ja) 2020-10-30 2022-05-05 学校法人慶應義塾 サルコペニア関連疾患等の新規治療および予防
EP4238979A4 (de) 2020-10-30 2024-09-25 Xeno-Interface Inc. Vernetztes beta-strang-peptid
TW202227481A (zh) 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
EP4240767A1 (de) 2020-11-06 2023-09-13 Amgen Inc. An cd3 bindende polypeptidkonstrukte
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
KR20230098334A (ko) 2020-11-06 2023-07-03 암젠 리서치 (뮌헨) 게엠베하 Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물
TW202233678A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增強的剪切特徵的多肽
EP4243936A1 (de) 2020-11-10 2023-09-20 Amgen Inc. Verfahren zur verabreichung eines bcma x cd3-bindenden moleküls
CN116547305A (zh) 2020-11-11 2023-08-04 生物技术公司 针对程序性死亡-1蛋白的单克隆抗体及其在医学中的用途
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
TW202237068A (zh) 2020-12-09 2022-10-01 美商建南德克公司 製備脂質奈米顆粒的高通量方法及其用途
DE102020134181A1 (de) 2020-12-18 2022-06-23 Henke-Sass, Wolf Gmbh Vorrichtung zum Applizieren eines Fluids
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
US12433847B2 (en) 2021-03-09 2025-10-07 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids
EP4305037B1 (de) 2021-03-12 2025-02-26 Bristol-Myers Squibb Company Kras inhibitoren
EP4314012A1 (de) 2021-03-24 2024-02-07 Bristol-Myers Squibb Company Immunmodulatoren
IL307519A (en) 2021-04-09 2023-12-01 Celldex Therapeutics Inc Antibodies against ILT4, anti-ILT4\PD-L1 bispecific antibody and their uses
WO2022221284A2 (en) 2021-04-12 2022-10-20 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
US20240384006A1 (en) 2021-05-06 2024-11-21 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
WO2022235654A1 (en) 2021-05-06 2022-11-10 Amgen Inc. Etelcalcetide formulations
EP4337197A1 (de) 2021-05-10 2024-03-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Pharmazeutische zusammensetzungen zur behandlung neurologischer erkrankungen
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
BR112023023831A2 (pt) 2021-05-26 2024-01-30 Oxford Biotherapeutics Ltd Métodos, combinação farmacêutica, anticorpo ou porção de ligação ao antígeno do mesmo
TW202313065A (zh) 2021-05-28 2023-04-01 美商季卡尼醫療公司 用於治療遺傳疾病之化合物
CA3217100A1 (en) 2021-06-09 2022-12-15 Gerald BURGSTALLER Novel anti-fibrotic drugs
EP4352077A1 (de) 2021-06-09 2024-04-17 Bristol-Myers Squibb Company Zyklische peptidimmunmodulatoren
US20240316194A1 (en) 2021-06-30 2024-09-26 Amgen Inc. Method of reconstituting lyophilized formulation
WO2023288213A1 (en) 2021-07-12 2023-01-19 Bristol-Myers Squibb Company Macrocyclic immunomodulators
KR20240035843A (ko) 2021-07-19 2024-03-18 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
MX2024000567A (es) 2021-07-20 2024-01-29 Regeneron Pharma Agentes similares a butirofilina 2 para tratar trastornos inflamatorios.
CN113398365B (zh) * 2021-07-21 2022-10-28 南京瑞淇卓越医疗美容诊所有限公司 一种心血管内科用的临床造影注射装置及注射方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
JP2024532763A (ja) 2021-08-11 2024-09-10 サノフィ パスツール インコーポレイテッド 切断型インフルエンザノイラミニダーゼおよびこれを使用する方法
MX2024002150A (es) 2021-08-20 2024-03-08 Intervet Int Bv Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
WO2023021170A2 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
KR20240076825A (ko) 2021-10-08 2024-05-30 사노피 파스퇴르 인크 다가 인플루엔자 백신
CN113831412B (zh) 2021-10-13 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd24的抗体及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
CN113754769B (zh) 2021-10-13 2023-06-06 宜明昂科生物医药技术（上海）股份有限公司 靶向cd70的抗体及其制备和用途
CN118176217A (zh) 2021-10-14 2024-06-11 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
JP2024540950A (ja) 2021-10-20 2024-11-06 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
IL312545A (en) 2021-11-05 2024-07-01 Sanofi Pasteur Inc Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them
EP4426345A1 (de) 2021-11-05 2024-09-11 Sanofi Multivalente hybridinfluenzaimpfstoffe mit hämagglutinin und neuraminidase sowie verfahren zur verwendung davon
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
JP2024540451A (ja) 2021-11-18 2024-10-31 オックスフォード バイオセラピューティックス リミテッド 組合せ医薬
WO2023096904A2 (en) 2021-11-24 2023-06-01 President And Fellows Of Harvard College C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
CN118613490A (zh) 2021-12-03 2024-09-06 百时美施贵宝公司 大环免疫调节剂
US12171779B2 (en) 2021-12-08 2024-12-24 University Of South Florida Regulated drug delivery via controlled degradable chondroitin sulfate particles
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
TW202334405A (zh) 2021-12-15 2023-09-01 美商英特瑞斯生物療法公司 假型分型之病毒顆粒、包含其之組合物及其用途
WO2023111153A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to human ngf
US20250340653A1 (en) 2021-12-16 2025-11-06 Intervet Inc. Caninized antibodies to canine interleukin-31 receptor alpha i
EP4447943A1 (de) 2021-12-16 2024-10-23 ModernaTX, Inc. Verfahren zur herstellung von lipidnanopartikeln
KR20240116755A (ko) 2021-12-17 2024-07-30 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
EP4457217A1 (de) 2021-12-30 2024-11-06 Curza Global LLC Antimikrobielle verbindungen und verfahren
JPWO2023145735A1 (de) 2022-01-25 2023-08-03
EP4469565A1 (de) 2022-01-27 2024-12-04 Sanofi Pasteur Modifizierte vero-zellen und verfahren zur verwendung davon zur virusherstellung
EP4469159A1 (de) 2022-01-27 2024-12-04 The Rockefeller University Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon
WO2023160610A1 (en) 2022-02-24 2023-08-31 Sinomab Bioscience Limited Bispecific binding proteins against alarmins and uses thereof
AU2023228405A1 (en) 2022-03-04 2024-10-10 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
US20250191693A1 (en) 2022-03-14 2025-06-12 Sanofi Pasteur, Inc. Machine-learning techniques in protein design for vaccine generation
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2023173393A1 (zh) 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
AU2023240941A1 (en) 2022-03-25 2024-09-19 Shanghai Henlius Biologics Co., Ltd. Anti-msln antibodies and methods of use
EP4499667A1 (de) 2022-03-28 2025-02-05 Bristol-Myers Squibb Company Makrocyclische immunomodulatoren
WO2023193002A1 (en) 2022-04-01 2023-10-05 Modernatx, Inc. Cross mixers for lipid nanoparticle production, and methods of operating the same
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
KR20250004836A (ko) 2022-04-26 2025-01-08 암젠 인크 동결건조 방법
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
GB202207263D0 (en) 2022-05-18 2022-06-29 Annexin Pharmaceuticals Ab Therapeutic compositions
KR20250012611A (ko) 2022-05-20 2025-01-24 브리스톨-마이어스 스큅 컴퍼니 거대고리 면역조절제
CN117186238A (zh) 2022-05-31 2023-12-08 宜明昂科生物医药技术（上海）股份有限公司 靶向pd-l1和vegf的重组融合蛋白及其制备和用途
WO2023235380A1 (en) 2022-06-01 2023-12-07 Zikani Therapeutics, Inc. Macrolides for treating genetic diseases
WO2023240189A1 (en) 2022-06-10 2023-12-14 Bristol-Myers Squibb Company Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
CN119630676A (zh) 2022-06-10 2025-03-14 百时美施贵宝公司 作为kras抑制剂的吡啶并[4,3-d]嘧啶衍生物
WO2023250513A1 (en) 2022-06-24 2023-12-28 Zikani Therapeutics, Inc. 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
JP2025524951A (ja) 2022-07-25 2025-08-01 インテリウス・バイオセラピューティクス・インコーポレイテッド 変異ポリペプチド、それを含む組成物、及びそれらの使用
EP4561547A1 (de) 2022-07-29 2025-06-04 ModernaTX, Inc. Lipidnanopartikelzusammensetzungen mit phospholipidderivaten und zugehörige verwendungen
WO2024026482A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
WO2024026475A1 (en) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
EP4568952A1 (de) 2022-08-11 2025-06-18 Bristol-Myers Squibb Company Kras-hemmer
IL318420A (en) 2022-08-16 2025-03-01 Bristol Myers Squibb Co Kras inhibitors
WO2024049994A1 (en) 2022-09-01 2024-03-07 Zikani Therapeutics, Inc. Treatment of familial adenomatous polyopsis using a 13-membered macrolide
JP2025530170A (ja) 2022-09-07 2025-09-11 ブリストル－マイヤーズ スクイブ カンパニー Ｋｒａｓ ｇ１２ｄ阻害剤
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
WO2024091918A2 (en) 2022-10-25 2024-05-02 Modernatx, Inc. Methods of lipid nanoparticle production in cross-mixers
IL320903A (en) 2022-11-21 2025-07-01 Dianthus Therapeutics Opco Inc Antibodies that bind to C1S and their uses
CN115737992B (zh) * 2022-11-24 2024-06-07 深圳市本尚医疗科技有限公司 无针注射器
WO2024115713A1 (en) 2022-11-30 2024-06-06 The Trustees Of The University Of Pennsylvania Brisc deubiquitinating enzyme inhibitors
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
AU2024222655A1 (en) 2023-02-13 2025-08-07 Intervet International B.V. Canine antibodies to canine il-4
WO2024170485A1 (en) 2023-02-13 2024-08-22 Intervet International B.V. Canine antibodies to canine il-13
EP4676956A2 (de) 2023-03-03 2026-01-14 Celldex Therapeutics, Inc. Anti-stammzellenfaktor (scf)- und anti-thymische stromalymphopoietin (tslp)-antikörper und bispezifische konstrukte
TW202440633A (zh) 2023-03-08 2024-10-16 美商安進公司 用於雙特異性分子的控制冰成核凍乾方法
AU2024235162A1 (en) 2023-03-16 2025-09-11 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
WO2024218322A1 (en) 2023-04-21 2024-10-24 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Ferroptosis inhibitors
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
WO2024236190A1 (en) 2023-05-18 2024-11-21 Annexin Pharmaceuticals Ab Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
WO2024240260A1 (zh) 2023-05-24 2024-11-28 南京金斯瑞生物科技有限公司 用于制备环状rna的载体和方法
WO2024246358A1 (en) 2023-06-01 2024-12-05 Sanofi Thermostable compositions comprising mrna lipid nanoparticles
WO2024259378A1 (en) 2023-06-14 2024-12-19 Amgen Inc. T cell engager masking molecules
WO2024259373A1 (en) 2023-06-14 2024-12-19 Modernatx, Inc. Compounds and compositions for delivery of therapeutic agents
WO2025006962A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025046492A1 (en) 2023-08-31 2025-03-06 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
TW202519262A (zh) 2023-09-06 2025-05-16 美商維里迪恩醫療股份有限公司 抗ｉｇｆ－１ｒ抗體之醫藥組合物
US20250090650A1 (en) 2023-09-06 2025-03-20 Sanofi Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
WO2025082594A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025083076A1 (en) 2023-10-17 2025-04-24 BioNTech SE Antigen binding proteins specifically binding to cd3 and their use in medicine
WO2025122619A1 (en) 2023-12-06 2025-06-12 Bristol-Myers Squibb Company Kras g12c inhibitors
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
WO2025160127A1 (en) 2024-01-23 2025-07-31 Modernatx, Inc. Ionizable lipids and compositions thereof for delivery of therapeutic agents
WO2025160381A1 (en) 2024-01-26 2025-07-31 Modernatx, Inc. Methods of preparing lipid nanoparticles
WO2025166202A1 (en) 2024-01-31 2025-08-07 Modernatx, Inc. Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025188845A1 (en) 2024-03-05 2025-09-12 Zenas Biopharma, Inc. STABLE FORMULATIONS FOR TNFα ANTIBODIES AND USES THEREOF
WO2025193571A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193574A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193573A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193583A1 (en) 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof
WO2025229127A1 (en) 2024-04-30 2025-11-06 Iomx Therapeutics Ag A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4643861A1 (de) 2024-04-30 2025-11-05 iOmx Therapeutics AG Halogenierter heteroarylkinasehemmer zur behandlung von weichgewebesarkom und gefässtumoren
EP4653460A1 (de) 2024-05-23 2025-11-26 Egle Therapeutics Il18r-agonist-antikörper und verwendungen davon
WO2025242910A1 (en) 2024-05-23 2025-11-27 Egle Therapeutics Il18r agonist antibodies and uses thereof
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
EP4670733A1 (de) 2024-06-27 2025-12-31 Sanofi Verfahren zur herstellung von viralen proteinen und deren verwendungen

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2704543A (en) * 1955-03-22 Hypo jet injector
US2101140A (en) * 1935-03-23 1937-12-07 Raymond W Hege Automatic injecting syringe device
US2380534A (en) * 1941-04-26 1945-07-31 Marshall L Lockhart Hypodermic injector
US2605763A (en) * 1948-01-31 1952-08-05 Becton Dickinson Co Injection device
US2547099A (en) * 1948-03-11 1951-04-03 Becton Dickinson Co Injection device and ampoule
US2680439A (en) * 1948-09-08 1954-06-08 Arnold K Sutermeister High-pressure injection device
US2670121A (en) * 1951-01-31 1954-02-23 Scherer Corp R P Flexible follower for metal ampoules
US2816543A (en) * 1954-07-12 1957-12-17 Scherer Corp R P Hypodermic injector
DE1287743B (de) * 1960-08-15 1969-01-23
US3292621A (en) * 1963-07-19 1966-12-20 Oscar H Banker Jet type protable inoculator
US3292622A (en) * 1964-09-21 1966-12-20 Oscar H Banker Power operated inoculator
US3424154A (en) * 1965-11-08 1969-01-28 Charles W Kinsley Injection system
US3561443A (en) * 1968-09-06 1971-02-09 Oscar H Banker Inoculator gun with delayed action
US3688765A (en) * 1969-10-03 1972-09-05 Jack S Gasaway Hypodermic injection device
US3945379A (en) * 1974-08-08 1976-03-23 Smithkline Corporation Injection device
JPS51130094A (en) * 1975-05-08 1976-11-12 Asahi Chemical Ind Twoostage pressure injector
CA1178503A (en) * 1982-05-27 1984-11-27 Health-Mor Personal Care Corporation Needleless hypodermic injector
HU186718B (en) * 1983-06-29 1985-09-30 Radelkis Electrokemiai Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4680027A (en) * 1985-12-12 1987-07-14 Injet Medical Products, Inc. Needleless hypodermic injection device
EP0250022A3 (de) * 1986-06-17 1988-06-22 SICIM SpA Tragbarer hypodermatischer Injektor
US4722728A (en) * 1987-01-23 1988-02-02 Patents Unlimited, Ltd. Needleless hypodermic injector
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) * 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
DE3814023A1 (de) * 1987-07-13 1989-01-26 Medizin Labortechnik Veb K Injektionsvorrichtung mit medikamentendepot
US5009637A (en) * 1987-11-16 1991-04-23 Sy-Quest International Limited Apparatus for hypodermic injection of liquids
US5073165A (en) * 1988-02-05 1991-12-17 Marpam International, Inc. Hypodermic jet injector and cartridge therefor
US4913699A (en) * 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US5024656A (en) * 1988-08-30 1991-06-18 Injet Medical Products, Inc. Gas-pressure-regulated needleless injection system
CA1325149C (en) * 1989-08-31 1993-12-14 Gavin Mcgregor Variable intensity remote controlled needleless injector
US5064413A (en) * 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5062830A (en) * 1990-04-04 1991-11-05 Derata Corporation Dry disposable nozzle assembly for medical jet injector
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43824E1 (en) 2001-01-11 2012-11-20 Powder Pharmaceuticals Inc. Needleless syringe
US8540665B2 (en) 2007-05-04 2013-09-24 Powder Pharmaceuticals Inc. Particle cassettes and processes therefor
US9044546B2 (en) 2007-05-04 2015-06-02 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor
US9358338B2 (en) 2007-05-04 2016-06-07 Powder Pharmaceuticals Incorporated Particle cassettes and processes therefor

Also Published As

Publication number Publication date
WO1994002188A1 (en) 1994-02-03
EP0651663A4 (de) 1995-08-30
EP0651663A1 (de) 1995-05-10
US5399163A (en) 1995-03-21
US5383851A (en) 1995-01-24
DE69327165T2 (de) 2000-08-24
DE69327165D1 (de) 2000-01-05
JP2004141667A (ja) 2004-05-20
US5520639A (en) 1996-05-28
JP3633615B2 (ja) 2005-03-30
AU4782793A (en) 1994-02-14
CA2140772A1 (en) 1994-02-03
AU676490B2 (en) 1997-03-13
JPH07509161A (ja) 1995-10-12
CA2140772C (en) 2006-07-11
ATE187083T1 (de) 1999-12-15

Similar Documents

Publication Publication Date Title
EP0651663B1 (de) Verfahren für nadellose subkutaninjektionen
WO1994002188A9 (en) Needleless hypodermic injection methods and device
US10918791B2 (en) Devices, systems and methods for medicament delivery
EP0427457B1 (de) Ampulle für nadelloses, hypodermisches Injektionsgerät
US6939319B1 (en) Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections
US8361029B2 (en) Devices, systems and methods for medicament delivery
US5312335A (en) Needleless hypodermic injection device
US4194505A (en) Containerized hypodermic module
US5049125A (en) Needleless injection apparatus of a liquid, notably for dental care
CA2476076C (en) Injector with bypass channel
US5024656A (en) Gas-pressure-regulated needleless injection system
AU675534B2 (en) Multiple medication injection apparatus and method
WO2004101025A2 (en) Needle free hypodermic injector and ampule for intradermal, subcutaneous and intramuscular injection
US20020099329A1 (en) Gas power sources for needle-less injector and needle-less injectors incorporating the same
GB2143737A (en) Needleless injector
JP2003529417A (ja) １回限り使用の使い捨て型ジェット注射器

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980507

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 19991201

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991201

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19991201

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19991201

REF Corresponds to:

Ref document number: 187083

Country of ref document: AT

Date of ref document: 19991215

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69327165

Country of ref document: DE

Date of ref document: 20000105

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000302

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000731

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120723

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120809

Year of fee payment: 20

Ref country code: DE

Payment date: 20120731

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69327165

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20130722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20130722